% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
\PassOptionsToPackage{dvipsnames,svgnames*,x11names*}{xcolor}
%
\documentclass[
  12pt,
]{memoir}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  pdftitle={Medicine},
  pdfauthor={Susmit},
  colorlinks=true,
  linkcolor=blue,
  filecolor=Maroon,
  citecolor=Blue,
  urlcolor=red,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\usepackage[margin=2cm]{geometry}
\usepackage{graphicx}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{-\maxdimen} % remove section numbering
\usepackage{graphicx}
\usepackage{subcaption}
\usepackage{hyperref}
\usepackage{pdfpages}
\usepackage{palatino}
\usepackage{tikz}
\usepackage{pgfplots}
\usetikzlibrary{positioning,arrows.meta}

\title{Medicine}
\author{Susmit}
\date{}

\begin{document}
\frontmatter
\includepdf[pages=1,fitpaper]{../pdfs/cover-medicine.pdf}
\maketitle

\mainmatter
\openany
\raggedbottom
\twocoltocetc
\tableofcontents

\pagebreak

\hypertarget{preface}{%
\chapter*{Preface}\label{preface}}
\addcontentsline{toc}{chapter}{Preface}

What follows are my own notes on various topics in medicine, mostly
based off of the following sources:

\begin{itemize}
\tightlist
\item
  \emph{Davidson's Principles and Practice of Medicine} 23rd ed.,
\item
  \emph{Oxford Handbook of Clinical Medicine} 10th ed.,
\item
  \emph{Long Cases in Clinical Medicine} 2nd ed.,
\item
  \emph{Short Cases in Clinical Medicine} 6th ed.
\end{itemize}

The date below tells you the last time when I edited this document, so
refer to that if you're worried about the temporal validity of the
contents. The chapters are arranged somewhat at random, partly
reflecting the order in which I studied them. These notes are, first and
foremost, for my personal use, so pardon the inconvenience. Over time I
will try tidying things up more. There's probably plenty of mistakes,
all my own. \textbf{Use at your own peril.}

\hfill Susmit Islam

\hfill 2022-07-14

\hypertarget{respiratory-medicine}{%
\chapter{Respiratory medicine}\label{respiratory-medicine}}

\hypertarget{tuberculosis}{%
\section{Tuberculosis}\label{tuberculosis}}

\hypertarget{side-effects-of-anti-tb-drugs}{%
\subsection{Side effects of anti-TB
drugs}\label{side-effects-of-anti-tb-drugs}}

\begin{itemize}
\tightlist
\item
  \textbf{Isoniazid:}

  \begin{itemize}
  \tightlist
  \item
    Hepatitis
  \item
    Rash
  \item
    B\(_6\) deficiency \(\rightarrow\) peripheral neuropathy (so
    pyridoxine supplement required during therapy)
  \end{itemize}
\item
  \textbf{Rifampicin:}

  \begin{itemize}
  \tightlist
  \item
    Hepatitis
  \item
    Rash
  \end{itemize}
\item
  \textbf{Pyrazinamide:}

  \begin{itemize}
  \tightlist
  \item
    Hepatitis
  \item
    Hyperuricaemia (rarely turns into gout)
  \end{itemize}
\item
  \textbf{Ethambutol:}

  \begin{itemize}
  \tightlist
  \item
    Retrobulbar neuritis (reversible)
  \item
    Arthralgia
  \end{itemize}
\item
  \textbf{Streptomycin:}

  \begin{itemize}
  \tightlist
  \item
    Ototoxicity (8th nerve palsy)
  \item
    Rash
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{cardiology}{%
\chapter{Cardiology}\label{cardiology}}

\hypertarget{presenting-problems-in-cvs-disease}{%
\section{Presenting problems in CVS
disease}\label{presenting-problems-in-cvs-disease}}

\hypertarget{features-of-benign-murmur}{%
\subsection{Features of benign murmur}\label{features-of-benign-murmur}}

\begin{itemize}
\tightlist
\item
  Soft
\item
  Midsystolic
\item
  Heard at left sternal edge
\item
  No radiation
\item
  No other cardiac abnormalities
\end{itemize}

\hypertarget{ecg}{%
\section{ECG}\label{ecg}}

\hypertarget{anatomy-of-an-ecg}{%
\subsection{Anatomy of an ECG}\label{anatomy-of-an-ecg}}

\begin{figure}
    \centering
    \includegraphics[width=0.7\textwidth]{../assets/med/ecg-anatomy.jpg}
    \caption{Parts of a normal ECG}
\end{figure}

\hypertarget{abnormalities-of-components}{%
\subsection{Abnormalities of
components}\label{abnormalities-of-components}}

\hypertarget{pathological-q}{%
\subsubsection{Pathological Q}\label{pathological-q}}

\begin{itemize}
\tightlist
\item
  Depth \textgreater{} 2mm
\item
  Height \textgreater{} 1mm
\item
  Present in \(\ge\) 2 leads
\item
  Assocd with loss of R height (Q \textgreater{} R/4; normally Q \(\le\)
  R/4)
\item
  \textbf{Indicates \emph{transmural} myocardial necrosis}
\end{itemize}

\hypertarget{segments-vs-intervals}{%
\subsubsection{Segments vs intervals}\label{segments-vs-intervals}}

\begin{itemize}
\tightlist
\item
  e.g.~ST segment = end of S \(\rightarrow\) start of T
\item
  PR interval = start of P \(\rightarrow\) start of R
\end{itemize}

\hypertarget{st-segment-elevation}{%
\subsubsection{ST segment elevation}\label{st-segment-elevation}}

\begin{itemize}
\tightlist
\item
  Normal: upto 1mm in limb leads, upto 2mm in chest leads
\item
  \textbf{Causes}

  \begin{itemize}
  \tightlist
  \item
    \textbf{STEMI:} \textbf{convexity} upwards
  \item
    \textbf{Acute periCArditis:}: \textbf{conCAvity} upwards
  \end{itemize}
\item
  \textbf{Indicates ongoing myocardial injury}
\end{itemize}

\hypertarget{myocardial-infarction}{%
\subsection{Myocardial infarction}\label{myocardial-infarction}}

\href{https://www.cvphysiology.com/CAD/CAD012}{A somewhat interesting
physiological explanation on how the changes arise}

\hypertarget{sites-of-infarction-based-on-lead}{%
\subsubsection{Sites of infarction based on
lead}\label{sites-of-infarction-based-on-lead}}

\begin{itemize}
\tightlist
\item
  Septal: V\(_1\), V\(_2\)
\item
  Anterior: V\(_3\), V\(_4\)
\item
  Lateral: I, aVL, V\(_5\), V\(_6\)
\item
  Extensive anterior: V\(_1\)-V\(_6\)
\item
  Anterolateral: I, aVL, V\(_1\)-V\(_6\)
\end{itemize}

\hypertarget{reciprocal-changes}{%
\subsubsection{Reciprocal changes}\label{reciprocal-changes}}

\begin{itemize}
\tightlist
\item
  Acute STEMI in some surface of the heart \(\rightarrow\) ST elevation
  in corresponding leads, and ST depression in reciprocal leads
\end{itemize}

\begin{figure}
\centering
\includegraphics[width=.6\textwidth]{../assets/med/reciprocal-leads.jpg}
\end{figure}

\pagebreak

\hypertarget{evolution-over-time-of-the-ecg-appearance-of-stemi}{%
\subsubsection{Evolution over time of the ECG appearance of
STEMI}\label{evolution-over-time-of-the-ecg-appearance-of-stemi}}

\begin{itemize}
\tightlist
\item
  STEMI = \textbf{complete proximal occlusion of major coronary artery}
\end{itemize}

\begin{figure}
\centering
\includegraphics[width=.5\textwidth]{../assets/med/STEMI.jpg}
\end{figure}

\begin{center}
$\fbox{A. Before the onset of infarction}$\\
$\downarrow$\\
$\fbox{B. In acute phase, ST elevation}$\\
$\downarrow$\\
$\fbox{C. Progressive loss of R and deepening Q}$\\
$\downarrow$\\
$\fbox{D. Resolution of ST elevation; fully developed pathological Q;
T inversion}$\\
$\downarrow$\\
$\fbox{E. In old infarcts, T-wave inversion may or may not persist}$\\
\end{center}

\begin{itemize}
\tightlist
\item
  ST elevation resolves after a few days
\end{itemize}

\pagebreak

\hypertarget{nstemi}{%
\subsubsection{NSTEMI}\label{nstemi}}

\begin{itemize}
\tightlist
\item
  \textbf{Partial occlusion of major} or \textbf{complete occlusion of
  minor} coronary artery
\item
  \emph{Subendocardial/partial-thickness MI} \(\rightarrow\) \textbf{no
  pathological Q}
\item
  \textbf{ST depression} + \textbf{T inversion} in chest leads
\end{itemize}

\hypertarget{coronary-artery-disease}{%
\section{Coronary Artery Disease}\label{coronary-artery-disease}}

\begin{itemize}
\tightlist
\item
  Diseases arising due to narrowing of the lumen of one or more coronary
  arteries and the resulting ischaemia/infarction of the myocardium or
  the conductive system.
\item
  \textbf{Types}:

  \begin{itemize}
  \tightlist
  \item
    Stable angina: Fixed atheromatous stenosis
  \item
    Unstable angina:

    \begin{itemize}
    \tightlist
    \item
      dynamic obstruction
    \item
      due to plaque rupture/erosion with thrombosis
    \end{itemize}
  \item
    MI
  \item
    Heart failure
  \item
    Arrhythmia
  \item
    Sudden cardiac death

    \begin{itemize}
    \tightlist
    \item
      ventricular arrhythmia
    \item
      asystole
    \item
      massive MI
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{arrhythmias}{%
\section{Arrhythmias}\label{arrhythmias}}

\hypertarget{classification-according-to-ecg-morphology}{%
\subsection{Classification according to ECG
morphology}\label{classification-according-to-ecg-morphology}}

\begin{itemize}
\tightlist
\item
  \textbf{Narrow complex}: QRS \textless{} 120ms (3 small sqs)

  \begin{itemize}
  \tightlist
  \item
    Sinus tachycardia
  \item
    Atrial fibrillation (irregular narrow complex tachycardia)
  \item
    Atrial flutter
  \item
    AV Nodal Re-entry Tachycardia (AVNRT aka SVT)
  \end{itemize}
\item
  \textbf{Broad complex}: QRS \textgreater{} 120ms (3 small sqs)

  \begin{itemize}
  \tightlist
  \item
    Ventricular tachycardia
  \item
    AV Re-entry Tachycardia (AVRT e.g.~Wolff-Parkinson-White syndrome)

    \begin{itemize}
    \tightlist
    \item
      Abnormal band of conductive tissue connecting atria and ventricles
      (accessory pathway)
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{management-of-svt}{%
\subsection{Management of SVT}\label{management-of-svt}}

\begin{itemize}
\tightlist
\item
  Carotid sinus massage or
\item
  Valsalva manoeuvre
\item
  If the manoeuvre fails,

  \begin{itemize}
  \tightlist
  \item
    Adenosine (3-12mg IV) or
  \item
    Rate-limiting CCB (Verapamil 5mg IV) or
  \item
    \(\beta\)-blocker
  \end{itemize}
\item
  If haemodynamic state compromised, DC cardioversion
\item
  Recurrent SVT \(\rightarrow\) catheter ablation
\end{itemize}

\hypertarget{atrial-fibrillation}{%
\section{Atrial fibrillation}\label{atrial-fibrillation}}

\hypertarget{causes}{%
\subsection{Causes}\label{causes}}

\begin{itemize}
\tightlist
\item
  \textbf{Cardiac}

  \begin{itemize}
  \tightlist
  \item
    CAD (including acute MI)
  \item
    Mitral stenosis (MS; rheumatic mitral valve disease)
  \item
    Hypertension
  \item
    Cardiomyopathy
  \end{itemize}
\item
  \textbf{Non-cardiac}

  \begin{itemize}
  \tightlist
  \item
    Thyrotoxicosis
  \item
    Pulmonary embolism
  \item
    Pneumonia
  \item
    Alcoholism
  \end{itemize}
\end{itemize}

\hypertarget{investigations}{%
\subsection{Investigations}\label{investigations}}

\begin{itemize}
\tightlist
\item
  ECG
\item
  Echo: to see valvular condition
\item
  Thyroid function test: to exclude thyrotoxicosis
\end{itemize}

\hypertarget{management-of-af}{%
\subsection{Management of AF}\label{management-of-af}}

\begin{itemize}
\tightlist
\item
  \textbf{Rhythm control}:

  \begin{itemize}
  \tightlist
  \item
    Pharmacological cardioversion

    \begin{itemize}
    \tightlist
    \item
      Pt stable + no history of heart disease \(\rightarrow\) IV
      flecainide
    \item
      Structural / ischaemic heart disease \(\rightarrow\) IV amiodarone
    \end{itemize}
  \item
    DC cardioversion if drugs fail
  \end{itemize}
\item
  \textbf{Rate control}

  \begin{itemize}
  \tightlist
  \item
    \(\beta\)-blockers
  \item
    Digoxin
  \item
    Rate-limiting CCB: verapamil / diltiazem
  \end{itemize}
\item
  \textbf{Thromboprophylaxis:}

  \begin{itemize}
  \tightlist
  \item
    Oral Warfarin
  \item
    Target INR: 2.0-3.0
  \item
    Reduces risk of stroke by \(\frac{2}{3}\)
  \item
    Start 4wks before cardioversion, continue till 3mo after successful
    cardioversion
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{myocardial-infarction-1}{%
\section{Myocardial Infarction}\label{myocardial-infarction-1}}

\hypertarget{management}{%
\subsection{Management}\label{management}}

\begin{figure}
\centering
\includegraphics[width=.7\textwidth]{../assets/med/MI-mx.png}
\vspace{5mm}
\caption{Management of acute MI}
\end{figure}

\pagebreak

\hypertarget{dermatology}{%
\chapter{Dermatology}\label{dermatology}}

\hypertarget{anatomy-and-physiology}{%
\section{Anatomy and physiology}\label{anatomy-and-physiology}}

\begin{figure}
    \centering
    \includegraphics[width=.5\textwidth]{../assets/surg/skin-layers.jpg}
    \caption{Layers of the skin}
\end{figure}

\begin{itemize}
\tightlist
\item
  \textbf{Layers of skin}:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Epidermis}: further layered into (from out\(\rightarrow\)in)

    \begin{itemize}
    \tightlist
    \item
      corneum
    \item
      lucidum
    \item
      granulosum
    \item
      spinosum
    \item
      basale
    \end{itemize}
  \item
    \textbf{Dermis}:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Papillary dermis}: more superficial part, containing

      \begin{itemize}
      \tightlist
      \item
        loose areolar tissue
      \item
        subpapillary vascular plexus
      \end{itemize}
    \item
      \textbf{Reticular dermis}: deeper part, containing

      \begin{itemize}
      \tightlist
      \item
        collagen
      \item
        deep vascular plexus
      \item
        nerves
      \item
        pilosebaceous units (hair follicle + sebaceous gland)
      \item
        sweat glands
      \item
        some keratinocytes around the hair follicles and sweat glands
        (important for wound healing - these are the reasons behind
        healing without scarring in upto partial-thickness skin wounds)
      \end{itemize}
    \end{itemize}
  \item
    Subcutis / subcutaneous tissue: (technically not part of the skin)
    adipose tissue
  \end{itemize}
\end{itemize}

\hypertarget{epidermal-appendages}{%
\subsection{Epidermal appendages}\label{epidermal-appendages}}

\begin{itemize}
\tightlist
\item
  Hair follicles:

  \begin{itemize}
  \tightlist
  \item
    phases of growth

    \begin{itemize}
    \tightlist
    \item
      anagen:

      \begin{itemize}
      \tightlist
      \item
        active growth
      \item
        lasts years in scalp hairs
      \end{itemize}
    \item
      catagen:

      \begin{itemize}
      \tightlist
      \item
        transitional
      \item
        lasts days (in scalp)
      \end{itemize}
    \item
      telogen:

      \begin{itemize}
      \tightlist
      \item
        resting
      \item
        lasts months (in scalp)
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  Sebaceous glands

  \begin{itemize}
  \tightlist
  \item
    usually \emph{associated with a hair follicle}
  \item
    \(\fbox{androgens}\rightarrow\) \textbf{\(\uparrow\)}
    \(\fbox{sebum}\)
  \item
    \(\fbox{oestrogen}\rightarrow\) \textbf{\(\downarrow\)}
    \(\fbox{sebum}\)
  \end{itemize}
\item
  Sweat glands

  \begin{itemize}
  \tightlist
  \item
    innerved by \emph{sympathetic cholinergic} fibres
  \end{itemize}
\end{itemize}

\hypertarget{principles-of-management-of-skin-disease}{%
\section{Principles of management of skin
disease}\label{principles-of-management-of-skin-disease}}

\hypertarget{topical-treatments}{%
\subsection{Topical treatments}\label{topical-treatments}}

\begin{itemize}
\tightlist
\item
  Ointments vs Creams

  \begin{itemize}
  \tightlist
  \item
    Ointments preferred to creams for dry skin (e.g.~chronic eczema) as

    \begin{itemize}
    \tightlist
    \item
      more hydrating

      \begin{itemize}
      \tightlist
      \item
        80\% oil + 20\% water in ointments (vs 50-50 for creams)
        \(\rightarrow\) prevent water loss from skin by oil layer
      \end{itemize}
    \item
      less preservatives \(\rightarrow\) less risk of allergy
    \end{itemize}
  \end{itemize}
\item
  Emollients

  \begin{itemize}
  \tightlist
  \item
    Moisturise, lubricate, protect skin
  \item
    \emph{Vehicles without active drug}
  \end{itemize}
\item
  Gluocorticoids
\end{itemize}

\hypertarget{phototherapy}{%
\subsection{Phototherapy}\label{phototherapy}}

\begin{itemize}
\tightlist
\item
  \textbf{UVB}
\item
  \textbf{Psoralen UVA}

  \begin{itemize}
  \tightlist
  \item
    Psoralen:

    \begin{itemize}
    \tightlist
    \item
      natural photosensitiser from plant source
    \item
      cross-link DNA strands on excitation with UVA
    \end{itemize}
  \item
    Cumulative exposure to PUVA \(\rightarrow\;\;\uparrow\) risk of SCC,
    so reserved for UVB resistance
  \end{itemize}
\item
  Uses

  \begin{itemize}
  \tightlist
  \item
    Psoriasis
  \item
    Atopic eczema
  \item
    Vitiligo
  \item
    Chronic urticaria
  \end{itemize}
\end{itemize}

\hypertarget{systemics}{%
\subsection{Systemics}\label{systemics}}

\begin{itemize}
\tightlist
\item
  Antihistamines
\item
  \textbf{Retinoids}

  \begin{itemize}
  \tightlist
  \item
    \emph{Anti-inflammatory}
  \item
    Promote \emph{differentiation of skin cells}
  \item
    \textbf{Teratogenic}

    \begin{itemize}
    \tightlist
    \item
      must be prescribed with robust contraception
    \item
      females must have negative pregnancy test before, during, and
      after therapy
    \end{itemize}
  \end{itemize}
\item
  \textbf{Immunosuppressants}

  \begin{itemize}
  \tightlist
  \item
    Glucocorticoids e.g.~prednisolone
  \item
    Methotrexate
  \item
    Azathioprine
  \end{itemize}
\end{itemize}

\hypertarget{biologics}{%
\subsection{Biologics}\label{biologics}}

\begin{itemize}
\tightlist
\item
  Biological \emph{inhibitors} of \emph{proinflammatory cytokines}
\item
  \textbf{TNF-\(\alpha\) inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Infliximab
  \item
    Etanercept
  \end{itemize}
\item
  \textbf{Interleukin inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Ustekinumab: IL-12, 23
  \item
    Guselkumab: IL-23
  \item
    Secukinumab: IL-17
  \end{itemize}
\item
  \emph{Rituximab}:

  \begin{itemize}
  \tightlist
  \item
    Binds to CD20 \(\rightarrow\) cause ADCC of B cells
  \item
    As terminally differentiated plasma cells don't have CD20 they're
    safe
  \item
    Use: pemphigus vulgaris
  \end{itemize}
\end{itemize}

\hypertarget{non-surgical-therapy}{%
\subsection{Non-surgical therapy}\label{non-surgical-therapy}}

\begin{itemize}
\tightlist
\item
  \textbf{Cryo}

  \begin{itemize}
  \tightlist
  \item
    \emph{Liquid N\(_2\)}
  \item
    Causes cell membrane destruction \(\rightarrow\) death
  \end{itemize}
\item
  Laser
\item
  PDT / photodynamic therapy
\end{itemize}

\hypertarget{skin-cancers}{%
\section{Skin cancers}\label{skin-cancers}}

\hypertarget{classification}{%
\subsection{Classification}\label{classification}}

\begin{itemize}
\tightlist
\item
  Non-melanoma skin cancer (NMSC): most common

  \begin{itemize}
  \tightlist
  \item
    SCC
  \item
    BCC
  \end{itemize}
\item
  Melanoma

  \begin{itemize}
  \tightlist
  \item
    Less common
  \item
    More metastatic risk \(\rightarrow\) cause of most skin cancer
    deaths
  \end{itemize}
\end{itemize}

\hypertarget{fungal-infections}{%
\section{Fungal infections}\label{fungal-infections}}

\hypertarget{types}{%
\subsection{Types}\label{types}}

\begin{itemize}
\tightlist
\item
  Superficial

  \begin{itemize}
  \tightlist
  \item
    Dermatophytes: aka \textbf{ringworm / tineasis}

    \begin{itemize}
    \tightlist
    \item
      \emph{Trichophyton}
    \item
      \emph{Epidermophyton}
    \item
      \emph{Microsporum}
    \end{itemize}
  \item
    Yeast
  \end{itemize}
\item
  Deep: less common

  \begin{itemize}
  \tightlist
  \item
    Chromomycosis
  \item
    Sporotrichosis
  \end{itemize}
\end{itemize}

\hypertarget{scabies}{%
\section{Scabies}\label{scabies}}

\hypertarget{agent}{%
\subsection{Agent}\label{agent}}

Caused by the mite \emph{Sarcoptis scabies hominis}

\hypertarget{diagnosis}{%
\subsection{Diagnosis}\label{diagnosis}}

\begin{itemize}
\tightlist
\item
  Identify the skin burrow
\item
  Visualize the mite by dermatoscope / extracting with a needle
\end{itemize}

\hypertarget{treatment}{%
\subsection{Treatment}\label{treatment}}

\begin{itemize}
\tightlist
\item
  Affected + all asymptomatic family members / physical contacts
\item
  Topical permethrin / malathion

  \begin{itemize}
  \tightlist
  \item
    2 applications
  \item
    1 wk apart
  \item
    Whole body, except head
  \end{itemize}
\item
  Oral Ivermectin:

  \begin{itemize}
  \tightlist
  \item
    Single dose
  \item
    For poor adherence, immunosuppresion or heavy infestation
  \end{itemize}
\end{itemize}

\hypertarget{acne}{%
\section{Acne}\label{acne}}

\begin{itemize}
\tightlist
\item
  \emph{Chronic inflammation} of \emph{pilosebaceous} units
\end{itemize}

\hypertarget{pathogenesis}{%
\subsection{Pathogenesis}\label{pathogenesis}}

Key components are:

\begin{itemize}
\tightlist
\item
  \(\uparrow\) Sebum production
\item
  Colonisation of pilosebaceous ducts by \emph{Propionibacterium acnes}
\item
  Occlusion of pilosebaceous ducts
\end{itemize}

\hypertarget{features}{%
\subsection{Features}\label{features}}

\begin{itemize}
\tightlist
\item
  Hallmark: \textbf{comedone}
\item
  Greasiness of skin
\end{itemize}

\hypertarget{management-1}{%
\subsection{Management}\label{management-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Mild disease}

  \begin{itemize}
  \tightlist
  \item
    Topical Benzoyl peroxide
  \item
    Topical Retinoids
  \item
    Topical antibiotics

    \begin{itemize}
    \tightlist
    \item
      Erythromycin
    \item
      Clindamycin
    \end{itemize}
  \end{itemize}
\item
  \textbf{Moderate disease}: topical \emph{plus}

  \begin{itemize}
  \tightlist
  \item
    Systemic tetracycline
  \item
    Oestrogen containing OCP
  \item
    Isotretinoin: if inadequate response to topical+systemic therapy for
    6 months
  \end{itemize}
\item
  \textbf{Severe disease}

  \begin{itemize}
  \tightlist
  \item
    Isotretinoin 0.5-1 mg/kg for 4 months:

    \begin{itemize}
    \tightlist
    \item
      Reduce sebum secretion and follicle colonisation
    \item
      Teratogen
    \item
      Pregnancy must be avoided during treatment \emph{and} within 2 mo
      of drug cessation
    \end{itemize}
  \item
    Systemic glucocorticoid (with isotretinoin)
  \item
    If unable to use isotretinoin

    \begin{itemize}
    \tightlist
    \item
      UVB phototherapy
    \item
      PDT
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{eczemas}{%
\section{Eczemas}\label{eczemas}}

\begin{itemize}
\tightlist
\item
  Seborrhoeic dermatitis is associated with \emph{Malassezia} yeasts
\end{itemize}

\hypertarget{features-1}{%
\subsection{Features}\label{features-1}}

Most types have the following clinical features:

\hypertarget{acute}{%
\subsubsection{Acute}\label{acute}}

\begin{itemize}
\tightlist
\item
  Ill-defined erythema, oedema
\item
  Papules, vesicles, bullae
\item
  Exudation
\item
  Scaling
\end{itemize}

\hypertarget{chronic}{%
\subsubsection{Chronic}\label{chronic}}

\begin{itemize}
\tightlist
\item
  Above features
\item
  Lichenification

  \begin{itemize}
  \tightlist
  \item
    Skin thickening with pronounced skin markings, 2\(^\circ\) to
    chronic scratching
  \item
    Fissures
  \item
    Dyspigmentation
  \end{itemize}
\end{itemize}

\hypertarget{management-2}{%
\subsection{Management}\label{management-2}}

\begin{figure}[h!]
\centering
\includegraphics[width=.7\textwidth]{../assets/med/eczema.jpg}
\vspace{-10mm}
\caption{Management of eczema}
\end{figure}

\pagebreak

\hypertarget{psoriasis}{%
\section{Psoriasis}\label{psoriasis}}

\begin{itemize}
\tightlist
\item
  Chronic inflammatory hyperproliferative skin disease
\item
  \textbf{Characteristics}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Well-defined erythematous scaly plaques}
  \item
    Affecting \textbf{extensor surfaces, scalp, nails}
  \end{itemize}
\end{itemize}

\hypertarget{histological-features}{%
\subsection{Histological features}\label{histological-features}}

\begin{itemize}
\tightlist
\item
  Keratinocyte hyperproliferation + abnormal differentiation
  \(\rightarrow\) nucleated stratum corneum cells (transit time from
  basale to corneum reduced to 5 from 28 \(\rightarrow\) keratinocytes
  reach the surface while immature)
\item
  Inflammation with Th-1 and Th-17 infiltration
\item
  Tortuosity of dermal capillaries and release of VEGF
\end{itemize}

\hypertarget{exacerbating-factors}{%
\subsection{Exacerbating factors}\label{exacerbating-factors}}

\begin{itemize}
\tightlist
\item
  \textbf{Sunlight}
\item
  \textbf{Trauma}
\item
  \textbf{Infection}

  \begin{itemize}
  \tightlist
  \item
    \(\beta\)-haemolytic strep \(\uparrow\) guttate psoriasis
  \item
    HIV may initally present with severe psoriasis
  \end{itemize}
\item
  \textbf{Drugs}

  \begin{itemize}
  \tightlist
  \item
    Antimalarials
  \item
    \(\beta\)-blockers
  \item
    Lithium
  \item
    NSAIDs
  \end{itemize}
\item
  \textbf{Stress and anxiety}
\end{itemize}

\hypertarget{clinical-types}{%
\subsection{Clinical types}\label{clinical-types}}

\begin{itemize}
\tightlist
\item
  \textbf{Plaque} psoriasis:

  \begin{itemize}
  \tightlist
  \item
    most common
  \item
    well-demarcated erythematous plaques
  \item
    silver-white scales in untreated

    \begin{itemize}
    \tightlist
    \item
      bleed on scraping (due to dilated vessels underneath)
      \(\rightarrow\) \textbf{Auspitz sign}
    \end{itemize}
  \item
    \textbf{Sites}

    \begin{itemize}
    \tightlist
    \item
      extensor surfaces

      \begin{itemize}
      \tightlist
      \item
        elbows
      \item
        knees
      \item
        lower back
      \end{itemize}
    \item
      scalp
    \item
      nails
    \end{itemize}
  \end{itemize}
\item
  \textbf{Guttate} psoriasis:

  \begin{itemize}
  \tightlist
  \item
    follows \emph{Strep} throat
  \item
    common in children/adolescent
  \item
    UVB highly effective
  \item
    may herald the onset of plaque psoriasis in adulthood
  \end{itemize}
\item
  \textbf{Erythrodermic} sporiasis: generalised \(\rightarrow\) medical
  emergency
\item
  \textbf{Pustular} psoriasis
\end{itemize}

\pagebreak

\hypertarget{management-3}{%
\subsection{Management}\label{management-3}}

\begin{figure}
\centering
\includegraphics[width=.7\textwidth]{../assets/med/psoriasis.jpg}
\caption{Management of psoriasis}
\end{figure}

\hypertarget{complications}{%
\subsection{Complications}\label{complications}}

\begin{itemize}
\tightlist
\item
  Psoriatic arthropathy
\item
  Exfoliative dermatitis
\item
  Secondary infection
\item
  Hyperuricaemia and gout
\end{itemize}

\pagebreak

\hypertarget{hypopigmentation}{%
\section{Hypopigmentation}\label{hypopigmentation}}

\hypertarget{causes-1}{%
\subsection{Causes}\label{causes-1}}

\begin{itemize}
\tightlist
\item
  Vitiligo
\item
  Albinism
\item
  Pityriasis alba
\item
  Pityriasis versicolor
\end{itemize}

\hypertarget{vitiligo}{%
\subsection{Vitiligo}\label{vitiligo}}

\begin{itemize}
\tightlist
\item
  \textbf{Acquired}
\item
  Cell-mediated \textbf{autoimmune destruction of melanocytes}
\item
  Loss of melanocytes \(\rightarrow\) hypopigmented patches
\end{itemize}

\hypertarget{albinism}{%
\subsection{Albinism}\label{albinism}}

\begin{itemize}
\tightlist
\item
  \textbf{Autosomal recessive}
\item
  \textbf{Reduced melanin production} by \textbf{normal number of
  melanocytes}
\item
  \(\uparrow\uparrow\) risk of sunburn, skin cancer
\end{itemize}

\hypertarget{hyperpigmentation}{%
\section{Hyperpigmentation}\label{hyperpigmentation}}

\hypertarget{causes-2}{%
\subsection{Causes}\label{causes-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Endocrine}

  \begin{itemize}
  \tightlist
  \item
    Melasma/chloasma:

    \begin{itemize}
    \tightlist
    \item
      in pregnancy / some OCP users
    \item
      discrete patches of facial pigmentation
    \end{itemize}
  \item
    Addison's disease
  \item
    Cushing's syndrome
  \item
    Nelson's syndrome

    \begin{itemize}
    \tightlist
    \item
      hyper-ACTH 2\(^\circ\) to bilateral adrenalectomy for Cushing's
    \item
      due to loss of -ve feedback from plasma cortisol
    \end{itemize}
  \item
    CKD
  \end{itemize}
\item
  \textbf{Drugs}

  \begin{itemize}
  \tightlist
  \item
    Amiodarone
  \item
    Anti-cancers:

    \begin{itemize}
    \tightlist
    \item
      Bleomycin: Hodgkin's
    \item
      Busulfan: CML
    \end{itemize}
  \item
    Choroquine
  \item
    Psoralens
  \end{itemize}
\end{itemize}

\hypertarget{stuff-not-large-enough-to-devote-a-section-to}{%
\section{Stuff not large enough to devote a section
to}\label{stuff-not-large-enough-to-devote-a-section-to}}

\hypertarget{spf-sun-protection-factor}{%
\subsection{SPF (sun protection
factor)}\label{spf-sun-protection-factor}}

\begin{itemize}
\tightlist
\item
  \(\frac{\LARGE{\text{UV dose for producing erythema with sunscreen}}} {\LARGE{\text{UV dose for producing erythema without sunscreen}}}\)
\end{itemize}

\hypertarget{mechanism-of-venous-ulceration}{%
\subsection{Mechanism of venous
ulceration}\label{mechanism-of-venous-ulceration}}

\begin{center}
\fbox{Incompetent valves} \\
$\downarrow$ \\
\fbox{$\uparrow$ capillary pressure} \\
$\downarrow$ \\
\fbox{Fibrinogen leaks out of capillary} \\
$\downarrow$ \\
\fbox{Forms fibrin clot around capillary (pericapillary cuffing)} \\
$\downarrow$ \\
\fbox{Impaired diffusion from capillaries} \\
$\downarrow$ \\
\fbox{Impaired oxygenation}
\end{center}

\pagebreak

\hypertarget{nephrology}{%
\chapter{Nephrology}\label{nephrology}}

\hypertarget{presenting-problems-in-urinary-disease}{%
\section{Presenting problems in urinary
disease}\label{presenting-problems-in-urinary-disease}}

\begin{itemize}
\tightlist
\item
  \textbf{Oliguria:} \textless{} 400mL/day
\item
  \textbf{Anuria:} \textless{} 100mL/day
\item
  \textbf{Haematuria:}

  \begin{itemize}
  \tightlist
  \item
    Healthy indiviuals may have upto 12,500 RBCs/mL
  \item
    Macroscopic or microscopic-dipstick+ haematuria indicates
    significant pathology
  \end{itemize}
\item
  \textbf{Proteinuria:}

  \begin{itemize}
  \tightlist
  \item
    Very small amounts of high molecular weight and moderate amounts of
    low molecular weight proteins pass through the healthy GBM
    (glomerular basement membrane)
  \item
    Whatever passes is also completely reabsorbed by receptors on
    tubular cells
  \item
    So in healthy individuals, \textless{} 150mg/day protein excreted
    through urine
  \item
    Transient proteinuria

    \begin{itemize}
    \tightlist
    \item
      Causes

      \begin{itemize}
      \tightlist
      \item
        Vigorous exercise
      \item
        Fever
      \item
        Heart failure
      \item
        UTI
      \end{itemize}
    \item
      Retest after trigger has resolved to verify if persistent
      proteinuria
    \end{itemize}
  \item
    Proteinuria best tested on early morning sample, as some have
    orthostatic proteinuria (benign, \textless{} 1g/day, associated with
    upright posture)
  \item
    Dipstick positive when \textgreater{} 0.5 g/day

    \begin{itemize}
    \tightlist
    \item
      If persistent dipstick proteinuria, 24h urinary protein must be
      quantified. \textgreater{} 1g/day \(\rightarrow\) likely
      glomerular disease
    \item
      PCR (Protein:Creatinine ratio) in spot sample might give better
      estimates than 24h protein as 24h urine collection is often
      inaccurate
    \item
      Renal biopsy to confirm dx in significant proteinuria
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{glomerular-diseases-glomerulonephritides}{%
\section{Glomerular diseases
(``Glomerulonephritides'')}\label{glomerular-diseases-glomerulonephritides}}

\hypertarget{introduction}{%
\subsection{Introduction}\label{introduction}}

\begin{itemize}
\tightlist
\item
  Though strictly means inflammation of the glomeruli, used to describe
  all glomerular disease (even if non-inflammatory e.g.~minimal change
  disease)
\item
  Lie on a \emph{spectrum}, from \emph{nephrosis} (podocyte pathology
  \(\rightarrow\) proteinuria) to \emph{nephritis} (inflammation + GBM
  damage \(\rightarrow\) haematuria)
\end{itemize}

\hypertarget{types-1}{%
\subsection{Types}\label{types-1}}

\hypertarget{nephrotic-presentation}{%
\subsubsection{Nephrotic presentation}\label{nephrotic-presentation}}

\begin{itemize}
\tightlist
\item
  \textbf{Minimal change disease}

  \begin{itemize}
  \tightlist
  \item
    Normal except on electron microscopy
  \item
    Electron microscopy shows fusion of podocyte foot processes
  \end{itemize}
\item
  Focal segmental glomerulosclerosis (FSGS)
\item
  \textbf{Membranous nephropathy}
\end{itemize}

\hypertarget{mild-glomerulonephritic-presentation}{%
\subsubsection{Mild glomerulonephritic
presentation}\label{mild-glomerulonephritic-presentation}}

\begin{itemize}
\tightlist
\item
  IgA nephropathy
\item
  Mesangiocapillary glomerulonephritis
\end{itemize}

\hypertarget{rapidly-progressive-glomerulonephritic-presentation}{%
\subsubsection{Rapidly progressive glomerulonephritic
presentation}\label{rapidly-progressive-glomerulonephritic-presentation}}

\begin{itemize}
\tightlist
\item
  Focal necrotising glomerulonephritis
\item
  Diffuse proliferative glomerulonephritis
\item
  Anti-GBM disease (aka Goodpasture's syndrome)
\end{itemize}

\section[Nephrotic syndrome]
    {Nephrotic syndrome
        \footnote
            {Most parts of this section, unless specifically
            mentioned to be for membranous nephropathy, refers to minimal
            change disease i.e. (most cases of) paediatric nephrotic
            syndrome}}

\hypertarget{features-2}{%
\subsection{Features}\label{features-2}}

\begin{itemize}
\tightlist
\item
  Massive \textbf{proteinuria} (\textgreater{} 3.5 g/day (medicine) or 1
  g/m\(^2\)/day (paediatrics))

  \begin{itemize}
  \tightlist
  \item
    \textbf{Hypoalbuminaemia} (\textless{} 3 g/dL)
  \item
    Generalised \textbf{oedema} (pitting)
  \item
    \textbf{``Effusions'':} Ascites, pleural effusion, pericardial
    effusion
  \end{itemize}
\item
  Features of reduced circulatory volume

  \begin{itemize}
  \tightlist
  \item
    Scanty urination (colour normal)
  \item
    Pulse: weak
  \item
    BP: low
  \item
    Capillary refill: prolonged (\textgreater{} 3s)
  \end{itemize}
\item
  Hyperlipidaemia \& lipiduria

  \begin{itemize}
  \tightlist
  \item
    due to \(\uparrow\) lipoprotein production by liver
  \end{itemize}
\item
  \textbf{Recurrent infections}

  \begin{itemize}
  \tightlist
  \item
    loss of immunoglobulins with urine
  \end{itemize}
\item
  Features of \textbf{complications}

  \begin{itemize}
  \tightlist
  \item
    Shiny abdominal wall, rigidity and tenderness, absent bowel sounds
    \(\rightarrow\) \textbf{peritonitis}, likely by \emph{Strep pneumo}
  \item
    Palpable kidney + haematuria \(\rightarrow\) \textbf{renal vein
    thrombosis}
  \item
    Alterations of consciousness, hemiplegia \(\rightarrow\)
    \textbf{stroke}
  \end{itemize}
\end{itemize}

\hypertarget{histopathology}{%
\subsection{Histopathology}\label{histopathology}}

\begin{itemize}
\tightlist
\item
  Histological types include

  \begin{itemize}
  \tightlist
  \item
    \textbf{Minimal change disease:}

    \begin{itemize}
    \tightlist
    \item
      no pathology visible with light microscope, visible pathology only
      under electron microscope.
    \item
      most common type in \textbf{children} (2-8y)
    \end{itemize}
  \item
    \textbf{Membranous nephropathy:} most common type in \textbf{adults}
  \end{itemize}
\end{itemize}

\hypertarget{aetiopathogenesis}{%
\subsection{Aetiopathogenesis}\label{aetiopathogenesis}}

\begin{figure}[h!]
    \centering
    \begin{subfigure}{.45\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/nephrotic-mcd.png}
        \caption{Minimal change disease}
    \end{subfigure}\hfill
    \begin{subfigure}{.45\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/nephrotic-mn.png}
        \caption{Membranous nephropathy}
    \end{subfigure}
    \vspace{5mm}
    \caption{Pathogenesis of nephrotic syndrome}
\end{figure}

\hypertarget{minimal-change-disease}{%
\subsubsection{Minimal change disease}\label{minimal-change-disease}}

\begin{itemize}
\tightlist
\item
  \textbf{Effacement of podocyte foot processes}
\end{itemize}

\hypertarget{membranous-nephropathy}{%
\subsubsection{Membranous nephropathy}\label{membranous-nephropathy}}

\begin{itemize}
\tightlist
\item
  \textbf{Autoantibodies to podocyte surface antigens} (e.g.~M-type
  phospholipase A\(_2\) receptor 1)\(\rightarrow\) \textbf{MAC-mediated
  glomerular capillary injury}

  \begin{itemize}
  \tightlist
  \item
    Antibodies to phospholipase A\(_2\) (PLA2Rab), thus, can be used for
    diagnosis without biopsy (but may be absent in early disease so
    biopsy might still be needed)
  \end{itemize}
\item
  Aetiology:

  \begin{itemize}
  \tightlist
  \item
    Primary / Idiopathic: HLA-DQA1
  \item
    Secondary:

    \begin{itemize}
    \tightlist
    \item
      Drugs e.g.~NSAIDs, penicillamine (treatment for Wilson's)
    \item
      Heavy metal poisoning
    \item
      Hep-B
    \item
      Malignancy
    \item
      SLE
    \end{itemize}
  \end{itemize}
\item
  Fates:

  \begin{itemize}
  \tightlist
  \item
    1/3 spontaneous remission
  \item
    1/3 remain nephrotic
  \item
    1/3 progressive CKD
  \end{itemize}
\end{itemize}

\hypertarget{investigations-1}{%
\subsection{Investigations}\label{investigations-1}}

\begin{itemize}
\tightlist
\item
  Urine RME

  \begin{itemize}
  \tightlist
  \item
    Albuminuria
  \item
    Granular \& hyaline casts
  \item
    Pus cells if associated with UTI
  \end{itemize}
\item
  Diagnostic

  \begin{itemize}
  \tightlist
  \item
    24h total protein: \textgreater{} 1g/m\(^2\)/day
  \item
    PCR (Protein-Creatinine ratio) \textgreater{} 2
  \item
    Serum albumin \textless{} 25 g/L
  \item
    Serum cholesterol \textgreater{} 220 mg/dL
  \end{itemize}
\item
  Renal biopsy: if nonresponsive to corticosteroid therapy
\end{itemize}

\hypertarget{treatment-1}{%
\subsection{Treatment}\label{treatment-1}}

\hypertarget{minimal-change-nephropathy}{%
\subsubsection{Minimal Change
Nephropathy}\label{minimal-change-nephropathy}}

\begin{itemize}
\tightlist
\item
  \textbf{Specific:}\footnote{\url{https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GD-Guideline-Key-Takeaways-for-Clinicians-Nephrotic-Syndrome-in-Children.pdf}}

  \begin{itemize}
  \tightlist
  \item
    \textbf{High dose glucocorticoid for 6wks}
  \item
    Prednisolone 1 mg/kg/day
  \item
    KDIGO guidelines: (4wks daily + 4wks alternate day) or (6wks daily +
    6wks alternate day)
  \end{itemize}
\item
  \textbf{Supportive:}

  \begin{itemize}
  \tightlist
  \item
    Diet:

    \begin{itemize}
    \tightlist
    \item
      normal with adequate protein
    \item
      salt restriction
    \end{itemize}
  \item
    Oedema: if severe,

    \begin{itemize}
    \tightlist
    \item
      restrict salt and fluid intake
    \item
      loop diuretics
    \end{itemize}
  \item
    Hypovolaemia: infuse albumin
  \item
    Infections: treat \& prevent (pneumococcus, meningococcus vaccine)
  \item
    Hypercoagulability:

    \begin{itemize}
    \tightlist
    \item
      due to loss of coagulation inhibitors (antithrombin III, protein
      C, protein S) + \(\uparrow\) liver production of procoagulants
    \item
      consider LMW heparin / warfarin if severe NS
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{membranous-nephropathy-1}{%
\subsubsection{Membranous Nephropathy}\label{membranous-nephropathy-1}}

\begin{itemize}
\tightlist
\item
  \textbf{Specific:}\footnote{\url{https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GD-Guideline-Key-Takeaways-for-Clinicians-Membranous-Nephropathy.pdf}}

  \begin{itemize}
  \tightlist
  \item
    \textbf{High-dose glucocorticoids + cyclophosphamide} (Ponticelli
    regimen)

    \begin{itemize}
    \tightlist
    \item
      Reserved for severe cases for risk of toxicity of this regimen
    \end{itemize}
  \item
    If secondary, \textbf{treat the underlying cause}
  \end{itemize}
\item
  \textbf{Supportive:} same as above
\end{itemize}

\hypertarget{acute-post-streptococcal-glomerulonephritis}{%
\section{Acute post-streptococcal
glomerulonephritis}\label{acute-post-streptococcal-glomerulonephritis}}

\hypertarget{pathogenesis-1}{%
\subsection{Pathogenesis}\label{pathogenesis-1}}

\begin{itemize}
\tightlist
\item
  Occurs following sore throat or skin infection by \textbf{group-A
  \(\beta\)-haemolytic streptococcus} (nephritogenic strains: 12, 49)
\item
  \textbf{Antibodies against streptococcal M protein cross-react} with
  glomerular antigens because of molecular mimicry
\item
  Complement activation, inflammatory cell infiltration. Net effects:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Oliguria}
  \item
    \textbf{Haematuria}
  \item
    Hypervolaemia, \textbf{hypertension}, hyperkalaemia
  \item
    \textbf{Oedema}
  \item
    \textbf{\(\downarrow\) Renal function} \(\implies\)

    \begin{itemize}
    \tightlist
    \item
      Azotaemia
    \item
      Acidosis
    \end{itemize}
  \end{itemize}
\item
  \textbf{Complications} (due mostly to acute hypertension)

  \begin{itemize}
  \tightlist
  \item
    Acute LVF
  \item
    Hypertensive encephalopathy
  \item
    Acute kidney injury
  \end{itemize}
\end{itemize}

\hypertarget{features-3}{%
\subsection{Features}\label{features-3}}

\begin{itemize}
\tightlist
\item
  Age: 5-12y; history of strep throat/skin infection a few wks prior
\item
  Scanty, smoky urine
\item
  Puffy face
\item
  Hypertension
\item
  Features of complications

  \begin{itemize}
  \tightlist
  \item
    \(\fbox{ALVF}\):

    \begin{itemize}
    \tightlist
    \item
      cough
    \item
      respiratory distress
    \item
      orthopnoea
    \item
      gallop rhythm
    \item
      bilateral basal crepitations
    \end{itemize}
  \item
    \(\fbox{Hypertensive encephalopathy}\):

    \begin{itemize}
    \tightlist
    \item
      headache, blurred vision, convulsion, delirium, papilloedema
    \end{itemize}
  \item
    \(\fbox{AKI}\): anuria
  \end{itemize}
\end{itemize}

\hypertarget{investigations-2}{%
\subsection{Investigations}\label{investigations-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Evidence of nephritis}

  \begin{itemize}
  \tightlist
  \item
    Urine RME:

    \begin{itemize}
    \tightlist
    \item
      RBC, RBC casts
    \item
      Mild proteinuria
    \item
      Leucocytes
    \end{itemize}
  \item
    Serum C3: \(\downarrow\)
  \item
    Serum C4: normal
  \end{itemize}
\item
  \textbf{Evidence of prior strep infection}

  \begin{itemize}
  \tightlist
  \item
    ASO titre: \(\uparrow\)
  \item
    Anti-DNAse B: \(\uparrow\)
  \end{itemize}
\item
  \textbf{Evidence of complications}

  \begin{itemize}
  \tightlist
  \item
    Serum electrolytes: may show hyperkalaemia and acidosis
  \item
    Serum creatinine
  \item
    X-ray chest
  \end{itemize}
\end{itemize}

\hypertarget{treatment-2}{%
\subsection{Treatment}\label{treatment-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Rest}
\item
  \textbf{Diet}: restrict fluid, salt, protein.
\item
  \textbf{Diuretics}: furosemide
\item
  \textbf{Antibiotics}: phenoxymethyl penicillin PO to prevent spread of
  remaining strep within the body
\item
  \textbf{Antihypertensive}
\end{itemize}

\hypertarget{alports-syndrome}{%
\section{Alport's syndrome}\label{alports-syndrome}}

\begin{itemize}
\tightlist
\item
  Mutation / deletion of COL4A5 on chr-X \(\rightarrow\) \textbf{defect
  of collagen type IV}
\item
  \textbf{X-linked recessive}
\item
  \(\fbox{Deposition of abnormal collagen}\;\rightarrow\;  \fbox{progressive degeneration of GBM}\)

  \begin{itemize}
  \tightlist
  \item
    Haematuria starts in early infancy
  \item
    ESRD by late teens / twenties
  \item
    Female carriers usually have haematuria, rarely significant renal
    disease
  \end{itemize}
\item
  Other basement membranes with collagen IV are also involved

  \begin{itemize}
  \tightlist
  \item
    cochlear BM \(\rightarrow\) \textbf{SNHL} (sensorineural hearing
    loss; especially in high-frequencies)
  \item
    \textbf{ocular abnormalities}:

    \begin{itemize}
    \tightlist
    \item
      lenticonus
    \item
      keratoconus
    \item
      cataracts
    \item
      corneal erosions
    \end{itemize}
  \end{itemize}
\item
  ACEi may slow (but not prevent) loss of renal function
\item
  Might require RRT (renal replacement therapy)
\end{itemize}

\hypertarget{adult-polycystic-kidney-disease}{%
\section{Adult Polycystic Kidney
Disease}\label{adult-polycystic-kidney-disease}}

\hypertarget{introduction-1}{%
\subsection{Introduction}\label{introduction-1}}

\begin{itemize}
\tightlist
\item
  Better known as Autosomal Dominant PKD (ADPKD)

  \begin{itemize}
  \tightlist
  \item
    There's a much rarer (1:20,000) autosomal recessive PKD (ARPKD)
  \end{itemize}
\item
  Prevalence 1:1000
\item
  \textbf{Autosomal dominant}
\item
  Small cysts lined by tubular epithelium develop from childhood,
  enlarge slowly
\item
  Surrounding normal kidney tissue compressed and progressively damaged
\item
  Mutations: PKD1 (in 85\%), PKD2 (15\%) (code for polycystin 1 and 2,
  respectively)
\end{itemize}

\hypertarget{features-4}{%
\subsection{Features}\label{features-4}}

\begin{itemize}
\tightlist
\item
  Asymptomatic initially
\item
  \textbf{Hypertension} from around 20 yrs of age
\item
  Either (or both) kidney may be palpable, nodular
\item
  Vague \textbf{loin discomfort} due to \textbf{enlarging mass}
\item
  Acute loin pain due to haemorrhage into a cyst
\item
  \textbf{Haematuria} with little / no proteinuria
\item
  About 30\% have \textbf{hepatic cysts} (mostly with no liver function
  impairment)
\item
  \textbf{Berry aneurysms} of cerebral vessels in \(\approx\) 5\% (may
  lead to SAH)
\item
  \textbf{Renal failure} \(\rightarrow\) features of CKD
\item
  Mitral / aortic regurgitation (frequent, rarely severe)
\end{itemize}

\hypertarget{investigations-3}{%
\subsection{Investigations}\label{investigations-3}}

\begin{itemize}
\tightlist
\item
  Dx is based on family history, clinical features, and USG
\item
  Criteria for dx in patients with +ve family history

  \begin{itemize}
  \tightlist
  \item
    15-39y: \(\ge\) 3 unilateral or bilateral cysts
  \item
    40-59y: \(\ge\) 2 cysts in each kidney (total: \(\ge\) 4)
  \item
    \(\ge\) 60y: \(\ge\) 4 cysts in each kidney (total: \(ge\) 8)
  \end{itemize}
\end{itemize}

\hypertarget{management-4}{%
\subsection{Management}\label{management-4}}

\begin{itemize}
\tightlist
\item
  \textbf{BP control:} 1st choice ACEi / ARBs
\item
  \textbf{Vasopressin V2 receptor antagonist:} Tolvaptan

  \begin{itemize}
  \tightlist
  \item
    Reduce kidney enlargement
  \item
    Slow rate of GFR decline
  \end{itemize}
\item
  \textbf{RRT} (renal replacement therapy) \textbf{:} dialysis /
  transplantation
\end{itemize}

\pagebreak

\hypertarget{renal-artery-stenosis}{%
\section{Renal artery stenosis}\label{renal-artery-stenosis}}

\hypertarget{introduction-2}{%
\subsection{Introduction}\label{introduction-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Most common cause of 2\(^{\circ}\) hypertension}
\item
  Most cases are due to \textbf{atherosclerosis}
\item
  Younger (\(\le\) 40) cases mostly non-atheromatous, due to
  \emph{fibromuscular dysplasia}
\end{itemize}

\hypertarget{pathophysiology}{%
\subsection{Pathophysiology}\label{pathophysiology}}

\begin{center}
\begin{tikzpicture}[
    FCT/.style={rectangle, draw=red!60, fill=red!5, very thick, minimum size
    =5 mm},
]
$\node[FCT] (Sten) {Renal artery stenosis};$
$\node[FCT] (Perf) [below=of Sten] {$\downarrow$ Renal perfusion pressure};$
$\node[FCT] (RAAS) [below=of Perf] {$\bigoplus$ Renin-angiotensin system};$
$\node[FCT] (Vasocons) [below left=25mm of RAAS, xshift=25mm] {Vasoconstriction};$
$\node[FCT] (Aldo) [below right=25mm of RAAS, xshift=-30mm] {$\uparrow$ Aldosterone production};$
$\node[FCT] (htn) [below=40mm of RAAS] {2$^{\circ}$ hypertension};$

$\draw[-{Stealth[length=5mm]}, very thick] (Sten.south) to node[right] {} (Perf.north);$
$\draw[-{Stealth[length=5mm]}, very thick] (Perf.south) to node[right] {} (RAAS.north);$
$\draw[-{Stealth[length=5mm]}, very thick] (RAAS.south) to node[right] {} (Vasocons.north);$
$\draw[-{Stealth[length=5mm]}, very thick] (RAAS.south) to node[right] {} (Aldo.north);$
$\draw[-{Stealth[length=5mm]}, very thick] (Vasocons.south) to node[right] {} (htn.north);$
$\draw[-{Stealth[length=5mm]}, very thick] (Aldo.south) to node[right] {} (htn.north);$

\end{tikzpicture}
\end{center}

\hypertarget{features-5}{%
\subsection{Features}\label{features-5}}

\begin{itemize}
\tightlist
\item
  Hypertension: may be severe and difficult to control
\item
  Acute pulmonary oedema: associated with severe hypertension
\item
  Progressive renal failure
\item
  Worsened renal function with ACEi or ARB administration (\(\ge\) 30\%
  increase in serum creatinine raises possibility of renal artery
  stenosis)
\item
  Peripheral vascular disease: associated, but not caused by the
  stenosis

  \begin{itemize}
  \tightlist
  \item
    In older patients with atherosclerotic renal artery stenosis (due to
    generalised atherosclerosis)
  \item
    Especially in legs
  \end{itemize}
\end{itemize}

\hypertarget{investigations-4}{%
\subsection{Investigations}\label{investigations-4}}

\begin{itemize}
\tightlist
\item
  CT / MR angiogram of renal vasculature: confirmatory
\item
  Serum creatinine: to see if worsening renal function
\item
  Plasma renin: may be elevated
\item
  Serum electrolytes: may be hypokalaemia due to hyperaldosteronism
\item
  USG: asymmetrically sized kidneys
\end{itemize}

\hypertarget{treatment-3}{%
\subsection{Treatment}\label{treatment-3}}

\hypertarget{medical}{%
\subsubsection{Medical}\label{medical}}

\begin{itemize}
\tightlist
\item
  Antihypertensives: not ACEi or ARB
\item
  Lipid-lowering agents: Statins
\item
  Anti-platelets: Low-dose aspirin
\end{itemize}

\hypertarget{surgical}{%
\subsubsection{Surgical}\label{surgical}}

\begin{itemize}
\tightlist
\item
  Angioplasty
\item
  Indications:

  \begin{itemize}
  \tightlist
  \item
    \(\le\) 40y age
  \item
    BP not controlled by antihypertensive / history of malignant htn
  \item
    History of flash pulmonary oedema
  \item
    Deteriorating renal function
  \end{itemize}
\end{itemize}

\hypertarget{thrombotic-microangiopathies-hus-ttp}{%
\section{Thrombotic microangiopathies (HUS,
TTP)}\label{thrombotic-microangiopathies-hus-ttp}}

\hypertarget{introduction-3}{%
\subsection{Introduction}\label{introduction-3}}

\begin{itemize}
\tightlist
\item
  Thrombotic occlusion of arterioles and capillaries especially in the
  kidneys or brain
\item
  Common feature of these is \textbf{microangiopathic haemolytic anaemia
  (MAHA)}

  \begin{itemize}
  \tightlist
  \item
    Haemolysis due to passage of RBCs through abnormal vessels
  \item
    \textbf{Schistocytes} (fragmented RBC) may be seen on PBF
  \item
    \textbf{Reticulocytosis}
  \item
    \textbf{\(\uparrow\) unconjugated bilirubin, serum LDH}
  \item
    \textbf{\(\downarrow\) serum haptoglobin}

    \begin{itemize}
    \tightlist
    \item
      Lysed RBCs release free Hb into the bloodstream. This can enter
      into tissues and trigger the inflammatory cascade, leading to
      tissue damage. To protect from this, the body comes equipped with
      a plasma protein called \emph{haptoglobin}, which binds to free
      Hb. When there's intravascular haemolysis, free Hb is released,
      and haptoglobin is used up, leading to its decreased serum levels.
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{haemolytic-uraemic-syndrome}{%
\subsection{Haemolytic uraemic
syndrome}\label{haemolytic-uraemic-syndrome}}

\begin{itemize}
\tightlist
\item
  Thrombotic microangiopathy predominantly involving renal
  microcirculation
\item
  Cause: \textbf{shiga-like toxin producing bacteria}

  \begin{itemize}
  \tightlist
  \item
    Enterohaemorrhagic \emph{Escherichia coli}
  \item
    \emph{Shigella dysenteriae}
  \end{itemize}
\item
  Most common cause of AKI in children
\item
  If no bloody diarrhoea, atypical causes of HUS (e.g.~complement system
  abnormalities - familial HUS) should be considered
\end{itemize}

\hypertarget{thrombotic-thrombocytopoenic-purpura}{%
\subsection{Thrombotic thrombocytopoenic
purpura}\label{thrombotic-thrombocytopoenic-purpura}}

\begin{itemize}
\tightlist
\item
  Thrombotic microangiopathy predominantly involving cerebral
  microcirculation
\item
  MAHA + thrombocytopoenia
\item
  Autoimmune: antibodies to ADAMTS-13

  \begin{itemize}
  \tightlist
  \item
    aka vWF cleaving protease

    \begin{itemize}
    \tightlist
    \item
      functions of vWF: haemostasis (thrombus + clot)

      \begin{itemize}
      \tightlist
      \item
        bind to and stabilize Factor VIII (unbound half-life: 1h, bound
        to vWF: 12h)
      \item
        help platelet aggregation
      \end{itemize}
    \end{itemize}
  \item
    destruction of ADAMTS-13 \(\rightarrow\;\;\uparrow\) vWF
    \(\rightarrow\) thrombosis
  \end{itemize}
\end{itemize}

\hypertarget{uti}{%
\section{UTI}\label{uti}}

\hypertarget{definition}{%
\subsection{Definition}\label{definition}}

\begin{itemize}
\tightlist
\item
  Presence of \textgreater{} 10\(^5\) organisms/mL in a mid-stream
  sample of urine (if asymptomatic).
\end{itemize}

\hypertarget{features-6}{%
\subsection{Features}\label{features-6}}

\begin{itemize}
\tightlist
\item
  \textbf{LUTI}: cystitis/urethritis

  \begin{itemize}
  \tightlist
  \item
    Frequency
  \item
    Urgency
  \item
    Dysuria (burning urethral pain during micturition)
  \item
    Haematuria
  \item
    Strangury (intense desire to pass more urine after voiding, due to
    spasm of inflamed bladder wall)
  \end{itemize}
\item
  \textbf{UUTI}: acute pyelonephritis

  \begin{itemize}
  \tightlist
  \item
    Fever with chills and rigor
  \item
    Vomiting
  \item
    Loin pain
  \item
    Renal angle tenderness
  \end{itemize}
\end{itemize}

\hypertarget{commonly-involved-pathogens}{%
\subsection{Commonly involved
pathogens}\label{commonly-involved-pathogens}}

\begin{itemize}
\tightlist
\item
  \emph{E. coli}: 75\%
\item
  \emph{Proteus}
\item
  \emph{Pseudomonas}
\item
  \emph{Streptococci}
\item
  \emph{Staph. epidermidis}
\end{itemize}

\hypertarget{investigations-5}{%
\subsection{Investigations}\label{investigations-5}}

\begin{itemize}
\tightlist
\item
  Dipstick test for nitrites, leucocyte esterase, and glucose

  \begin{itemize}
  \tightlist
  \item
    Most urinary pathogens (e.g.~\emph{E. coli, Proteus} etc) reduce
    nitrate to nitrite
  \item
    UTI \(\rightarrow\) Neutrophils in urine \(\rightarrow\) leucocyte
    esterase
  \end{itemize}
\item
  Microscopy for WBC and organisms
\item
  Urine culture
\end{itemize}

\hypertarget{treatment-4}{%
\subsection{Treatment}\label{treatment-4}}

\hypertarget{cystitis}{%
\subsubsection{Cystitis}\label{cystitis}}

\begin{itemize}
\tightlist
\item
  \textbf{1st choice}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Trimethoprim} (200mg bds 3 days)
  \item
    \textbf{Nitrofurantoin} (50mg qds 3 days)
  \end{itemize}
\item
  \textbf{Pregnancy}

  \begin{itemize}
  \tightlist
  \item
    Nitrofurantoin (50mg qds 7 days)
  \item
    Cefalexin (250mg qds 7 days)
  \end{itemize}
\item
  Avoid trimethoprim during pregnancy, and nitrofurantoin at term
\end{itemize}

\hypertarget{pyelonephritis}{%
\subsubsection{Pyelonephritis}\label{pyelonephritis}}

\begin{itemize}
\tightlist
\item
  \textbf{1st choice}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Cefalexin} (1g qds 14 days)
  \item
    \textbf{Ciprofloxacin} (500mg bds 7 days)
  \end{itemize}
\item
  Hospitalise if no response within 24h
\end{itemize}

\hypertarget{epididymo-orchitis}{%
\subsubsection{Epididymo-orchitis}\label{epididymo-orchitis}}

\begin{itemize}
\tightlist
\item
  \emph{1st choice}: Ciprofloxacin
\end{itemize}

\hypertarget{acute-prostatitis}{%
\subsubsection{Acute prostatitis}\label{acute-prostatitis}}

\begin{itemize}
\tightlist
\item
  \emph{1st choice}: Trimethoprim
\end{itemize}

\hypertarget{prophylactic-measures-in-women-with-recurrent-uti}{%
\subsection{Prophylactic measures in women with recurrent
UTI}\label{prophylactic-measures-in-women-with-recurrent-uti}}

\begin{itemize}
\tightlist
\item
  Fluid intake \(\ge\) 2L/day
\item
  Regular complete bladder evacuation
\item
  Emptying the bladder before and after intercourse
\item
  Good personal hygiene
\item
  Continuous prophylactic trimethoprim (100mg) and nitrofurantoin (50
  mg) at night
\end{itemize}

\pagebreak

\hypertarget{stuff-not-large-enough-to-devote-a-section-to-1}{%
\section{Stuff not large enough to devote a section
to}\label{stuff-not-large-enough-to-devote-a-section-to-1}}

\pagebreak

\hypertarget{rheumatology}{%
\chapter{Rheumatology}\label{rheumatology}}

\hypertarget{investigations-of-musculoskeletal-disease}{%
\section{Investigations of musculoskeletal
disease}\label{investigations-of-musculoskeletal-disease}}

\hypertarget{joint-fluid-aspiration}{%
\subsection{Joint fluid aspiration}\label{joint-fluid-aspiration}}

\begin{itemize}
\tightlist
\item
  Normal:

  \begin{itemize}
  \tightlist
  \item
    Amount small
  \item
    Viscosity high
  \item
    Colourless / pale yellow
  \end{itemize}
\item
  Inflammation:

  \begin{itemize}
  \tightlist
  \item
    Amount raised
  \item
    Viscosity lowered (due to enzymatic degradation of hyaluronan \&
    aggrecan)
  \item
    Turbid (due to neutrophils)
  \end{itemize}
\item
  Crystal-induced arthropathies

  \begin{itemize}
  \tightlist
  \item
    Crystals seen by polarised light microscopy
  \item
    Urate crystals \(\rightarrow\) long, needle shaped, -ve
    birefringence
  \item
    Ca pyrophosphate crystals \(\rightarrow\) small, rhomboid, +ve
    birefringence
  \end{itemize}
\end{itemize}

\hypertarget{bone-scintigraphy}{%
\subsection{Bone scintigraphy}\label{bone-scintigraphy}}

\begin{itemize}
\tightlist
\item
  Dx of metastatic bone disease and Paget's
\item
  \(^{99}\)Tc radiolabelled bisphosphonate used
\end{itemize}

\hypertarget{dexa-dual-emission-x-ray-absorptiometry}{%
\subsection{DEXA (Dual Emission X-ray
Absorptiometry)}\label{dexa-dual-emission-x-ray-absorptiometry}}

\begin{itemize}
\tightlist
\item
  Measure BMD (bone mineral density)

  \begin{itemize}
  \tightlist
  \item
    \textless{} -2.5 \(\rightarrow\) osteoporosis
  \item
    Between -2.5 and -1 \(\rightarrow\) osteopoenia
  \item
    \textgreater{} 2.5 \(\rightarrow\) high bone mass (most common cause
    osteoarthritis)
  \end{itemize}
\end{itemize}

\hypertarget{immunology}{%
\subsection{Immunology}\label{immunology}}

\begin{itemize}
\tightlist
\item
  \textbf{RF}

  \begin{itemize}
  \tightlist
  \item
    Antibody to Fc fragment of human Ig
  \item
    70\% sensitive for RA (if nodules \& extra-articular manifestations
    then 100\% sensitive); specificity poor
  \item
    \textbf{RF +ve diseases}

    \begin{itemize}
    \tightlist
    \item
      Rheumatoid arthritis
    \item
      Sjogren's syndrome
    \item
      SLE
    \item
      Old age (\textgreater{} 65)
    \end{itemize}
  \end{itemize}
\item
  \textbf{ACPA}

  \begin{itemize}
  \tightlist
  \item
    Antibody to peptides in which arginine has been converted to
    citrulline by peptidylarginine deiminase, an enzyme abundant in
    inflamed synovium.
  \item
    70\% sensitive, \textgreater95\% specific for RA
  \end{itemize}
\item
  \textbf{ANA} (antinuclear antibodies)

  \begin{itemize}
  \tightlist
  \item
    100\% sensitive for SLE but poor specificity
  \item
    \textbf{ANA +ve diseases}

    \begin{itemize}
    \tightlist
    \item
      SLE
    \item
      Sjogren's
    \item
      Systemic sclerosis
    \item
      Rheumatoid arthritis
    \end{itemize}
  \end{itemize}
\item
  \textbf{Complement C3}

  \begin{itemize}
  \tightlist
  \item
    Active SLE \(\rightarrow\;\;\downarrow\) C3 (due to consumption of
    C3 by immune complexes)
  \end{itemize}
\end{itemize}

\hypertarget{seropositive-vs-seronegative-arthritis}{%
\section{Seropositive vs Seronegative
arthritis}\label{seropositive-vs-seronegative-arthritis}}

\begin{itemize}
\tightlist
\item
  Seropositive: RF+ inflammatory arthritis

  \begin{itemize}
  \tightlist
  \item
    Rheumatoid arthritis
  \item
    SLE
  \end{itemize}
\item
  Seronegative: RF- inflammatory arthritis

  \begin{itemize}
  \tightlist
  \item
    Ankylosing spondylitis
  \item
    Reactive arthritis
  \item
    Psoriatic arthropathy
  \end{itemize}
\end{itemize}

\hypertarget{osteoarthritis}{%
\section{Osteoarthritis}\label{osteoarthritis}}

\begin{itemize}
\tightlist
\item
  Characterised by

  \begin{itemize}
  \tightlist
  \item
    degeneration of articular cartilage
  \item
    subchondral osteosclerosis
  \item
    osteophyte formation at joint margin
  \item
    enlargement of affected joint
  \end{itemize}
\item
  Sites

  \begin{itemize}
  \tightlist
  \item
    hips
  \item
    knees
  \item
    PIPs
  \item
    DIPs
  \item
    cervical and lumbar spine
  \end{itemize}
\item
  Investigations:

  \begin{itemize}
  \tightlist
  \item
    X-ray of affected joint: findings described above in characteristics
  \item
    MRI spine if spine OA + suspected root compression / spinal stenosis
  \end{itemize}
\item
  Treatment

  \begin{itemize}
  \tightlist
  \item
    Conservative:

    \begin{itemize}
    \tightlist
    \item
      Wt loss
    \item
      Exercise
    \item
      NSAIDs
    \item
      Intraarticular glucocorticoids
    \end{itemize}
  \item
    Surgical: if refractory

    \begin{itemize}
    \tightlist
    \item
      Total joint replacement
    \item
      Osteotomy
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{spondyloarthropathies}{%
\section{Spondyloarthropathies}\label{spondyloarthropathies}}

\begin{itemize}
\tightlist
\item
  Asymmetrical oligoarthrites associated with HLA-B27 and typically
  involving the spine

  \begin{itemize}
  \tightlist
  \item
    Ankylosing spondylitis
  \item
    Reactive arthritis
  \item
    Psoriatic arthropathy
  \item
    Axial spondyloarthritis
  \item
    Entropathic spondyloarthritis (arthritis associated with IBD)
  \end{itemize}
\item
  Common features:

  \begin{itemize}
  \tightlist
  \item
    Asymmetric oligoarthritis
  \item
    Sacroilitis
  \item
    Enthesitis (inflammation where tendon attaches to bone)
  \end{itemize}
\end{itemize}

\hypertarget{reactive-arthritis}{%
\subsection{Reactive arthritis}\label{reactive-arthritis}}

\begin{itemize}
\tightlist
\item
  ``Reactive'' to certain infections e.g.~\emph{Chlamydia, Campylobacter
  Salmonella, Shigella}.
\item
  \textbf{Reiter's syndrome}:

  \begin{itemize}
  \tightlist
  \item
    Triad of \emph{can't see, can't pee, can't bend the knee}

    \begin{itemize}
    \tightlist
    \item
      \textbf{Conjunctivitis}
    \item
      \textbf{Urethritis}
    \item
      \textbf{Reactive arthritis}
    \end{itemize}
  \item
    Due to \emph{Chlamydia}
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{neurology}{%
\chapter{Neurology}\label{neurology}}

\hypertarget{raised-icp}{%
\section{Raised ICP}\label{raised-icp}}

\begin{itemize}
\tightlist
\item
  Normal ICP = \textbf{5-15 mmHg}
\end{itemize}

\hypertarget{causes-3}{%
\subsection{Causes}\label{causes-3}}

\begin{itemize}
\tightlist
\item
  \textbf{ICSOL}

  \begin{itemize}
  \tightlist
  \item
    Intracranial haemorrhage
  \item
    Tumours e.g.~glioma
  \item
    Brain abscess
  \end{itemize}
\item
  \textbf{Hydrocephalus}: blockade of CSF circulation

  \begin{itemize}
  \tightlist
  \item
    Obstructive / non-communicating
  \item
    Communicating
  \end{itemize}
\item
  \textbf{Cerebral oedema} e.g.~meningoencephilitis
\item
  \textbf{Venous sinus obstruction} e.g.~cerebral venous thrombosis
\end{itemize}

\hypertarget{features-7}{%
\subsection{Features}\label{features-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Headache}
\item
  \textbf{Vomiting}
\item
  \textbf{Diplopia / blurred vision}: Due to \emph{6th nerve palsy}

  \begin{itemize}
  \tightlist
  \item
    6th nerve palsy due to

    \begin{itemize}
    \tightlist
    \item
      stretching of the long, slender nerve
    \item
      compression against petrous temporal bone
    \end{itemize}
  \item
    This palsy of the 6th nerve secondary to raised ICP is known as a
    \emph{false localisation sign}. If the patient presented only with
    visible features of 6th nerve palsy, (e.g.~diplopia, medial squint)
    we would falsely localise the primary defect to the 6th nerve. So in
    6th nerve palsy always exclude RICP by looking for papilloedema.
  \end{itemize}
\item
  \textbf{Depressed consciousness}
\item
  \textbf{Papilloedema}
\item
  \textbf{Bradycardia}
\item
  \textbf{Hypertension}
\end{itemize}

\hypertarget{management-5}{%
\subsection{Management}\label{management-5}}

\begin{itemize}
\tightlist
\item
  According to cause:

  \begin{itemize}
  \tightlist
  \item
    Mass lesion \(\rightarrow\) surgical decompression
  \item
    Hydrocephalus \(\rightarrow\) \emph{ventriculoperitoneal shunt}
    operation
  \item
    Oedema \(\rightarrow\) glucocorticoids
  \end{itemize}
\item
  Supportive:

  \begin{itemize}
  \tightlist
  \item
    Head elevation
  \item
    Fluid balance
  \item
    BP control
  \item
    Diuretics: mannitol
  \end{itemize}
\end{itemize}

\hypertarget{neurological-emergencies}{%
\section{Neurological emergencies}\label{neurological-emergencies}}

\begin{itemize}
\tightlist
\item
  \textbf{Status epilepticus}
\item
  \textbf{Stroke} (if thrombo)
\item
  \textbf{Subarachnoid haemorrhage}
\item
  \textbf{Cord compression}
\item
  \textbf{GBS}
\item
  \textbf{Myasthenia gravis} (if bulbar and/or respiratory)
\end{itemize}

\pagebreak

\hypertarget{status-epilepticus}{%
\section{Status epilepticus}\label{status-epilepticus}}

\hypertarget{definition-1}{%
\subsection{Definition}\label{definition-1}}

\begin{itemize}
\tightlist
\item
  Continuous or recurrent \textbf{seizures} for \textbf{\(\ge\) 30 mins
  without gain of consciousness} in between.
\item
  Clinically we assume SE after 5mins of seizure activity.
\end{itemize}

\hypertarget{management-6}{%
\subsection{Management}\label{management-6}}

\includegraphics[width=.7\textwidth]{../assets/med/stat-epi.png}

\hypertarget{all-jerks-root-values}{%
\section{All jerks root values}\label{all-jerks-root-values}}

\begin{itemize}
\tightlist
\item
  Biceps: C5
\item
  Supinator: C6
\item
  Triceps: C7
\item
  Finger (aka Hoffmann test): C8
\item
  Knee: L3, L4
\item
  Ankle: S1, S2
\item
  Plantar: S1 (technically not a jerk since it's a superficial reflex)
\end{itemize}

\pagebreak

\hypertarget{subarachnoid-haemorrhage}{%
\section{Subarachnoid haemorrhage}\label{subarachnoid-haemorrhage}}

\hypertarget{causes-4}{%
\subsection{Causes}\label{causes-4}}

\begin{itemize}
\tightlist
\item
  Ruptured berry aneurysm (85\%)
\item
  Arterio-venous malformations
\end{itemize}

\hypertarget{features-8}{%
\subsection{Features}\label{features-8}}

\begin{itemize}
\tightlist
\item
  Sudden severe ``thunderclap'' headache (often occipital)
\item
  Vomiting
\item
  High BP
\item
  Neck stiffness
\item
  May be loss of consciousness
\item
  Photophobia
\end{itemize}

\hypertarget{investigations-6}{%
\subsection{Investigations}\label{investigations-6}}

\begin{itemize}
\tightlist
\item
  CT scan: hyperdense material in the subarachnoid space
\item
  Lumbar puncture: blood, xanthochromia
\end{itemize}

\hypertarget{management-7}{%
\subsection{Management}\label{management-7}}

\begin{itemize}
\tightlist
\item
  \textbf{Nimodipine} 30-60mg IV for 5-14d, followed by 360mg oral for
  7d

  \begin{itemize}
  \tightlist
  \item
    \emph{prevents delayed ischaemia}
  \end{itemize}
\item
  Insertion of \textbf{Pt coils} into aneurysm
\item
  \textbf{Surgical clipping} of the neck of the aneurysm
\item
  Surgical removal if AVM
\end{itemize}

\hypertarget{subacute-combined-degeneration}{%
\section{Subacute combined
degeneration}\label{subacute-combined-degeneration}}

\hypertarget{features-9}{%
\subsection{Features}\label{features-9}}

\begin{itemize}
\tightlist
\item
  \textbf{Peripheral neuropathy}: due to \textbf{demyelination}
\item
  Signs of \textbf{dorsal column lesion}: \textbf{position and vibration
  sense lost}
\item
  Signs of \textbf{pyramidal lesion}:

  \begin{itemize}
  \tightlist
  \item
    \textbf{plantar extensor}
  \item
    \textbf{knee jerk brisk}
  \item
    \textbf{ankle jerk absent}: as peripheral neuropathy affects longer
    nerves first, the afferent pathway for ankle jerk is damaged by the
    PN while the same for knee jerk is not. Combined with the
    corticospinal tract lesion, this makes knee jerks brisk and ankle
    jerks absent.
  \end{itemize}
\item
  \textbf{Optic atrophy}: death of retinal ganglion cell axons
\end{itemize}

\pagebreak

\hypertarget{cauda-equina-and-conus-medullaris-lesions}{%
\section{Cauda equina and Conus medullaris
lesions}\label{cauda-equina-and-conus-medullaris-lesions}}

\hypertarget{anatomy}{%
\subsection{Anatomy}\label{anatomy}}

\begin{figure}[h!]
    \begin{subfigure}[b]{.4\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/cauda.jpg}
        \vspace*{10mm}
        \caption{The Conus and the Cauda}
    \end{subfigure}\hfill
    \begin{subfigure}[b]{.4\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/cauda-2.jpg}
        \caption{Vertebrae with corresponding spinal cord segments}
    \end{subfigure}
\end{figure}

\begin{itemize}
\tightlist
\item
  During development, the spine grows faster than the spinal cord, which
  is why the spinal nerves exit the spinal column at increasingly
  oblique angles.
\item
  The spinal cord ends as the tapered conus medullaris at around L1.
\end{itemize}

\pagebreak

\hypertarget{relevant-physiology}{%
\subsection{Relevant physiology}\label{relevant-physiology}}

\begin{itemize}
\tightlist
\item
  S2-4:

  \begin{itemize}
  \tightlist
  \item
    Parasympathetic fibres for bladder sphincter (activation causes
    emptying)
  \item
    Somatic fibres for pudendal nerves (activation causes relaxation of
    urethral and anal sphincters \(\rightarrow\) emptying).
  \end{itemize}
\item
  Conus is surrounded by spinal nerve roots bundled up together around
  it, so injury / compression in this region leads to a combination of
  UMN and LMN lesion features.
\item
  Lesion in the cauda region leads only to LMN lesion features as
  there's no cord there.
\end{itemize}

\hypertarget{features-of-cauda-equina-syndrome-vs-conus-medullaris-syndrome}{%
\subsection{Features of Cauda Equina syndrome vs Conus Medullaris
syndrome}\label{features-of-cauda-equina-syndrome-vs-conus-medullaris-syndrome}}

\begin{figure}
\centering
\includegraphics[width=.7\textwidth]{../assets/med/cauda-vs-conus-1.png}
\end{figure}
\begin{figure}
\centering
\includegraphics[width=.75\textwidth]{../assets/med/cauda-vs-conus-2.png}
\vspace{10mm}
\end{figure}

\hypertarget{neurogenic-bladder}{%
\section{Neurogenic Bladder}\label{neurogenic-bladder}}

\hypertarget{physiological-control-of-micturition-the-micturition-reflex}{%
\subsection{Physiological control of micturition: the Micturition
Reflex}\label{physiological-control-of-micturition-the-micturition-reflex}}

\hypertarget{components}{%
\subsubsection{``Components''}\label{components}}

\begin{itemize}
\tightlist
\item
  \textbf{Detrusor muscle}

  \begin{itemize}
  \tightlist
  \item
    Muscles of the bladder wall
  \item
    Innervated by

    \begin{itemize}
    \tightlist
    \item
      \textbf{Parasympathetic:}

      \begin{itemize}
      \tightlist
      \item
        cholinergic M\(_3\) receptors
      \item
        pelvic nerve from \textbf{S2-4}
      \item
        causes \textbf{contraction} \(\rightarrow\) \textbf{urination}
      \end{itemize}
    \item
      \textbf{Sympathetic:}

      \begin{itemize}
      \tightlist
      \item
        \(\beta_3\) receptors
      \item
        hypogastric nerve from \textbf{T10-L2}
      \item
        causes \textbf{relaxation} \(\rightarrow\) \textbf{storage} /
        retention
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Internal urethral sphincter}

  \begin{itemize}
  \tightlist
  \item
    Innervated by \textbf{only sympathetic}

    \begin{itemize}
    \tightlist
    \item
      hypogastric nerve from \textbf{T10-L2}
    \item
      causes storage / retention
    \end{itemize}
  \end{itemize}
\item
  \textbf{External urethral sphincter}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Voluntary control}

    \begin{itemize}
    \tightlist
    \item
      UMN from pontine micturition centre
    \item
      LMN from S2-4 (pudendal nerve)
    \item
      causes retention
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{the-big-picture-highest-yield-for-clinical-interpretation}{%
\subsubsection{The big picture (highest yield for clinical
interpretation)}\label{the-big-picture-highest-yield-for-clinical-interpretation}}

\begin{figure}
\centering
\includegraphics[width=.6\textwidth]{../assets/med/micturition-reflex.png}
\end{figure}

\begin{center}
$\fbox{Lesion in S}$ $\rightarrow$ $\fbox{Stores (retention)}$\\
$\fbox{Lesion in L and above}$ $\rightarrow$ $\fbox{Leaks (incontinence)}$\\

\end{center}

\begin{itemize}
\tightlist
\item
  The reflex spontaneously tries to void the bladder upon being filled
  even by small amounts. The only thing holding it back is the pontine
  micturition centre which always inhibits the circuit, unless we
  voluntarily signal it not to. We can't signal the bladder to empty
  itself. We can only signal the micturition reflex to not hold back.
\item
  The reflex circuit is composed of afferents and efferents from S2-4.
  So any \textbf{lesion above S2-4} will leave the circuit intact, while
  damaging the telephone lines from the pontine centre. The end result
  is that we lose the inhibition of the reflex (which fires every few
  mins after storing some tens of millilitres of urine), and without
  anything holding it back, there's urinary \textbf{incontinence}.
\item
  On the other hand, any \textbf{lesion at S2-4} will damage the circuit
  elements themselves. That means that the reflex will be lost. This
  means we no longer have access to the bladder emptying circuit. So
  there will be urinary \textbf{retention}.
\end{itemize}

\pagebreak

\hypertarget{the-details}{%
\subsubsection{The details}\label{the-details}}

\begin{figure}
    \centering
    \begin{subfigure}{.4\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/mic-part.png}
        \vspace{6mm}
        \caption{Partly filled bladder}
    \end{subfigure}\hfill
    \begin{subfigure}{.55\textwidth}
        \includegraphics[width=\textwidth]{../assets/med/mic-filled.png}
        \vspace{6mm}
        \caption{Fully filled bladder}
    \end{subfigure}
    \vspace{10mm}
    \caption{Neural control of micturition}

\end{figure}

\pagebreak

\hypertarget{parkinsons-disease}{%
\section{Parkinson's disease}\label{parkinsons-disease}}

\hypertarget{parkinsonism}{%
\subsection{Parkinsonism}\label{parkinsonism}}

\begin{itemize}
\tightlist
\item
  Triad of \textbf{TRH}: tremor, rigidity, hypokinesia (bradykinesia)
\item
  \textbf{Causes}

  \begin{itemize}
  \tightlist
  \item
    Idiopathic \(\rightarrow\) Parkinson's disease
  \item
    Cerebrovascular disease
  \item
    Drugs:

    \begin{itemize}
    \tightlist
    \item
      Antipsychotics (older)
    \item
      Metoclopramide (D\(_2\) blocker \(\rightarrow\) undo D\(_2\)
      mediated inhibition of cholinergic stimulation in GIT
      \(\rightarrow\) \(\uparrow\)GI motility \(\rightarrow\)
      antiemesis)

      \begin{itemize}
      \tightlist
      \item
        Domperidone, which is also a D\(_2\) blocker, selectively acts
        on D\(_2\)s in the GIT, so no parkinsonism
      \item
        Metoclopramide is nonselective
      \end{itemize}
    \item
      Na-valproate, Lithium
    \end{itemize}
  \item
    Other neurodegenerative diseases

    \begin{itemize}
    \tightlist
    \item
      Lewy body dementia
    \item
      Multiple system atrophy
    \item
      Alzheimer's
    \end{itemize}
  \item
    Genetic

    \begin{itemize}
    \tightlist
    \item
      Huntington's
    \item
      Wilson's
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{pathophysiology-1}{%
\subsection{Pathophysiology}\label{pathophysiology-1}}

\begin{itemize}
\tightlist
\item
  Loss of pigmented dopaminergic neurons in substantia nigra
\item
  \textbf{Lewy bodies in nigral cells}: pathological hallmark

  \begin{itemize}
  \tightlist
  \item
    Eosinophilic cytoplasmic inclusions
  \item
    Lewy body = aggregation of \(\alpha\)-synuclein (hence the
    alternative name \(\alpha\)-synucleinopathy)
  \item
    Other \(\alpha\)-synucleinopathies (diseases associated with Lewy
    body deposition (differ in the initial site of deposition and hence
    initial features)):

    \begin{itemize}
    \tightlist
    \item
      Lewy body dementia
    \item
      Multiple system atrophy
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{features-10}{%
\subsection{Features}\label{features-10}}

\begin{itemize}
\tightlist
\item
  Average age of onset: 60y
\item
  First degreee relative with PD \(\rightarrow\) 2-3x risk
\item
  Progressive, incurable
\item
  Initially motor symptoms dominate, but eventually nonmotor symptoms
  (e.g.~depression, anxiety, cognitive impairment) become increasingly
  prominent
\item
  Motor symptoms \textbf{initially asymmetrical}
\item
  The hallmark is \textbf{bradykinesia}, which leads to

  \begin{itemize}
  \tightlist
  \item
    Micrographia (small handwriting)
  \item
    Difficulty tying shoelaces / buttoning clothes
  \item
    Difficulty rolling over in bed
  \end{itemize}
\item
  \textbf{Resting tremor} affecting limbs, chin and jaw but not the head
\item
  \textbf{Rigidity}
\item
  Soft, indistinct speech
\end{itemize}

\hypertarget{signs}{%
\subsubsection{Signs}\label{signs}}

\begin{itemize}
\tightlist
\item
  General:

  \begin{itemize}
  \tightlist
  \item
    Hypomimia (expressionless / mask-like face)
  \item
    Dysphonia (soft, indistinct speech)
  \item
    Flexed (stooped) posture with impaired postural reflexes
  \item
    Bradykinesia
  \item
    \textbf{Glabellar tap:}

    \begin{itemize}
    \tightlist
    \item
      tapping on glabella (above bridge of nose) \(\rightarrow\) blink
    \item
      normal \(\rightarrow\) blinking stops after 3-5 times
    \item
      Parkinson's \(\rightarrow\) sustained blinking
    \end{itemize}
  \end{itemize}
\item
  Gait: \textbf{Festinating gait}

  \begin{itemize}
  \tightlist
  \item
    Slow to start
  \item
    Short, shuffling steps (festination)
  \item
    Reduced arm swing
  \item
    Impaired balance on turning (fractionated turn)
  \end{itemize}
\item
  Tremor:

  \begin{itemize}
  \tightlist
  \item
    First in arm/hand (\textbf{pill-rolling} tremor)
  \end{itemize}
\item
  Rigidity:

  \begin{itemize}
  \tightlist
  \item
    \textbf{Leadpipe rigidity}:

    \begin{itemize}
    \tightlist
    \item
      better seen in elbow / knee
    \item
      uniform throughout movement
    \end{itemize}
  \item
    \textbf{Cogwheel rigidity} (= tremor superimposed on rigidity)
    better seen in wrist
  \item
    Rigidity vs Spasticity:

    \begin{itemize}
    \tightlist
    \item
      Rigidity:

      \begin{itemize}
      \tightlist
      \item
        uniform resistance throughout range of motion
      \item
        due to \emph{extrapyramidal} lesion
      \end{itemize}
    \item
      Spasticity:

      \begin{itemize}
      \tightlist
      \item
        initially increased resistance, followed by lessening
      \item
        due to \emph{pyramidal} lesion
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  The following will be normal (if abnormal, consider other causes)

  \begin{itemize}
  \tightlist
  \item
    Power, jerks, plantar
  \item
    Eye movements
  \item
    Sensory exam
  \item
    Cerebellar exam
  \end{itemize}
\end{itemize}

\hypertarget{investigations-7}{%
\subsection{Investigations}\label{investigations-7}}

\begin{itemize}
\tightlist
\item
  Dx is clinical
\item
  CT / MRI normal
\item
  Functional dopaminergic imaging (SPECT / PET) abnormal even early
\item
  In younger, exclude Huntington's and Wilson's
\end{itemize}

\hypertarget{treatment-5}{%
\subsection{Treatment}\label{treatment-5}}

\begin{itemize}
\tightlist
\item
  \textbf{Only symptomatic, no cure}
\item
  \textbf{Physiotherapy \(\pm\) drugs} (drugs not given if mild)
\item
  \textbf{Surgical:} on failure of medical therapy
\end{itemize}

\hypertarget{drugs}{%
\subsubsection{Drugs}\label{drugs}}

\begin{itemize}
\tightlist
\item
  \textbf{Levodopa + carbidopa}

  \begin{itemize}
  \tightlist
  \item
    Most effective in reducing \textbf{rigidity and bradykinesia}
  \item
    \textbf{Role of dietary protein}: amino acids in dietary protein
    compete with levodopa for intestinal absorption and transport across
    BBB \(\rightarrow\;\;\downarrow\) efficacy of levodopa
  \item
    Side effects:

    \begin{itemize}
    \tightlist
    \item
      Postural hypotension
    \item
      Nausea, vomiting
    \item
      Hallucinations
    \end{itemize}
  \item
    Fluctuating response after 3-5y of use

    \begin{itemize}
    \tightlist
    \item
      \emph{End of dose dyskinesia}: due to progressive loss of
      dopamine, duration of action of levodopa becomes shorter. Freezing
      and rigidity before next dose of levodopa.

      \begin{itemize}
      \tightlist
      \item
        Management: smaller, frequent dosage
      \end{itemize}
    \item
      \emph{On-off phenomenon}: periods of severe parkinsonism (freezing
      and immobility - \emph{off period}) alternating with periods of
      dopamine-induced dyskinesia / chorea (\emph{on period}).

      \begin{itemize}
      \tightlist
      \item
        Management: lower levodopa dose, add selegiline with levodopa
      \end{itemize}
    \end{itemize}
  \item
    Contraindications:

    \begin{itemize}
    \tightlist
    \item
      Psychosis
    \item
      Narrow angle glaucoma
    \item
      Malignant melanoma
    \item
      PUD
    \end{itemize}
  \end{itemize}
\item
  \textbf{Anticholinergics}

  \begin{itemize}
  \tightlist
  \item
    Benzhexol, benztropine, trihexyphenidyl
  \item
    Reduce \textbf{tremor and rigidity}, not bradykinesia
  \item
    Side effects:

    \begin{itemize}
    \tightlist
    \item
      Urinary retention, constipation, dry mouth
    \item
      Worsening of glaucoma
    \end{itemize}
  \item
    Contraindications:

    \begin{itemize}
    \tightlist
    \item
      BEP
    \item
      Narrow angle glaucoma
    \end{itemize}
  \end{itemize}
\item
  \textbf{Dopamine receptor agonists}

  \begin{itemize}
  \tightlist
  \item
    Ergot-derived (e.g.~bromocriptine) or non-ergot-derived (e.g.
    ropinirole)
  \item
    Compared to levodopa, less therapeutic effect, more side effects
  \item
    Side effects:

    \begin{itemize}
    \tightlist
    \item
      Postural hypotension
    \item
      Nausea, vomiting
    \item
      Hallucination
    \item
      Confusion
    \end{itemize}
  \end{itemize}
\item
  \textbf{MAO-B inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Selegiline, rasagiline
  \item
    MAO-B facilitates dopamine breakdown \(\rightarrow\) MAO-Bi
    potentiates the action of levodopa by inhibiting breakdown
  \end{itemize}
\item
  \textbf{COMT inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Tolcapone, entacapone
  \item
    COMT \(\rightarrow\) peripheral breakdown of levodopa
  \end{itemize}
\item
  \textbf{Amantadine}:

  \begin{itemize}
  \tightlist
  \item
    Rarely used unless patient unable to tolerate other drugs.
  \item
    Mild, short-lived effect.
  \end{itemize}
\end{itemize}

\hypertarget{surgery}{%
\subsubsection{Surgery}\label{surgery}}

\begin{itemize}
\tightlist
\item
  \textbf{Deep brain stimulation}

  \begin{itemize}
  \tightlist
  \item
    Replaced destructive surgery
  \item
    Targets: thalamus, globus pallidus, subthalamic nuclei
  \item
    Thalamic stimulation \(\rightarrow\) reduce tremor
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{diabetes-mellitus}{%
\chapter{Diabetes Mellitus}\label{diabetes-mellitus}}

\hypertarget{mechanism-of-insulin-secretion}{%
\section{Mechanism of insulin
secretion}\label{mechanism-of-insulin-secretion}}

\begin{figure}
\centering
\includegraphics[width=.7\textwidth]{../assets/med/insulin-secr.jpg}
\caption{Mechanism of insulin secretion}
\end{figure}

\hypertarget{incretin-effect}{%
\section{Incretin effect}\label{incretin-effect}}

For the same glucose load applied orally and IV, the \textbf{oral load
stimulates more insulin secretion} (because oral load \(\rightarrow\)
release of gut peptides GLP-1 and GIP \(\rightarrow\;\;\uparrow\)
insulin secretion).

\vfill

\begin{figure}[h!]
\centering
\includegraphics[width=.4\textwidth]{../assets/med/incretin.png}
\vspace{10mm}
\caption{The incretin effect}
\end{figure}

\hypertarget{diabetic-ketoacidosis-dka}{%
\section{Diabetic ketoacidosis (DKA)}\label{diabetic-ketoacidosis-dka}}

\begin{itemize}
\tightlist
\item
  \textbf{Medical emergency}
\item
  Cause of death

  \begin{itemize}
  \tightlist
  \item
    Children: cerebral oedema
  \item
    Adults:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Hypokalaemia}
    \item
      ARDS
    \item
      Comorbidities: acute MI, sepsis, pneumonia
    \end{itemize}
  \end{itemize}
\item
  \textbf{Cardinal biochemical features}

  \begin{itemize}
  \tightlist
  \item
    Hyperglycaemia \(\rightarrow\) osmotic diuresis \(\rightarrow\)
    dehydration, dyselectrolytaemia
  \item
    Hyperketonaemia:

    \begin{itemize}
    \tightlist
    \item
      Insulin deficiency + elevated catecholamines \(\rightarrow\)
      unrestrained lipolysis to make FFA \(\rightarrow\) hepatic
      ketogenesis
    \end{itemize}
  \item
    Metabolic acidosis
  \end{itemize}
\end{itemize}

\hypertarget{clinical-features}{%
\subsection{Clinical features}\label{clinical-features}}

\begin{itemize}
\tightlist
\item
  \textbf{Symptoms}

  \begin{itemize}
  \tightlist
  \item
    Polyuria, thirst
  \item
    Weakness
  \item
    Nausea, vomiting
  \item
    Abdominal pain
  \item
    Blurred vision
  \end{itemize}
\item
  \textbf{Signs}

  \begin{itemize}
  \tightlist
  \item
    Dehydration
  \item
    Hypotension
  \item
    Tachycardia
  \item
    Air hunger / Kussmaul breathing (deep and sighing breathing)
  \item
    Acetone breath
  \item
    Delirium, drowsiness, coma
  \end{itemize}
\end{itemize}

\hypertarget{management-8}{%
\subsection{Management}\label{management-8}}

\begin{itemize}
\tightlist
\item
  \textbf{Establish IV access}
\item
  \textbf{Volume replacement: 0.9\% NaCl }

  \begin{itemize}
  \tightlist
  \item
    If systolic BP \(\ge\) 90mmHg: 1L over 1h
  \item
    Else: \(\frac{1}{2}\)L over 15mins \(\rightarrow\) reassess. If BP
    still \textless{} 90mmHg, repeat.
  \end{itemize}
\item
  \textbf{Insulin therapy}: \textbf{IV} 0.1 U/kg/h

  \begin{itemize}
  \tightlist
  \item
    Corrects hyperglycaemia \& acidosis
  \end{itemize}
\item
  \textbf{Monitor}

  \begin{itemize}
  \tightlist
  \item
    Every 1h:

    \begin{itemize}
    \tightlist
    \item
      capillary blood glucose and ketone
    \item
      vitals: pulse, BP, resp rate, O\(_2\) sat, urine output
    \end{itemize}
  \item
    Every 2h: Venous HCO\(_3^{-}\) and K\(^+\)
  \item
    Every 4h: Serum electrolytes
  \end{itemize}
\item
  If K\(^+\) is low, 40mmol/L KCl with normal saline
\end{itemize}

\hypertarget{hypoglycaemia}{%
\section{Hypoglycaemia}\label{hypoglycaemia}}

\hypertarget{features-11}{%
\subsection{Features}\label{features-11}}

\begin{itemize}
\tightlist
\item
  \textbf{Autonomic}

  \begin{itemize}
  \tightlist
  \item
    Sweating
  \item
    Trembling
  \item
    Palpitations
  \end{itemize}
\item
  \textbf{Neuroglycopoenic}

  \begin{itemize}
  \tightlist
  \item
    Delirium
  \item
    Drowsiness
  \item
    Speech difficulty
  \item
    Incoordination
  \end{itemize}
\end{itemize}

\hypertarget{management-9}{%
\subsection{Management}\label{management-9}}

\begin{figure}
\centering
\includegraphics[width=.7\textwidth]{../assets/med/hypogly.png}
\vspace{5mm}
\caption{Managing hypoglycaemia}
\end{figure}

\begin{itemize}
\tightlist
\item
  Oral fast-acting carbohydrate (10-15g) e.g.~glucose drink /
  confectionery / honey to buccal mucosa
\item
  Repeat capillary glucose measurement 10-15mins later

  \begin{itemize}
  \tightlist
  \item
    If still hypo, repeat upto 3 cycles
  \item
    Still hypo after 3 cycles \(\rightarrow\) glucagon 1mg IM
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{insulin-therapy}{%
\section{Insulin therapy}\label{insulin-therapy}}

\hypertarget{indications}{%
\subsection{Indications}\label{indications}}

\begin{itemize}
\tightlist
\item
  Type I DM
\item
  Type II DM not controlled by OHA
\item
  DIP / GDM
\item
  DKA
\item
  Hyperkalaemia
\end{itemize}

\hypertarget{preparations}{%
\subsection{Preparations}\label{preparations}}

\begin{itemize}
\tightlist
\item
  \textbf{Rapid-acting} (rapid=LAG-less)

  \begin{itemize}
  \tightlist
  \item
    Lispro
  \item
    Aspart
  \item
    Glulisine
  \end{itemize}
\item
  \textbf{Short-acting:} soluble/regular insulin
\item
  \textbf{Intermediate-acting:} Isophane (I for I)
\item
  \textbf{Long-acting}

  \begin{itemize}
  \tightlist
  \item
    Glargine (gLARGE-in)
  \item
    Detemir Route of administration: \textbf{subcutaneous}
  \end{itemize}
\end{itemize}

\hypertarget{oral-hypoglycaemic-agents}{%
\section{Oral Hypoglycaemic Agents}\label{oral-hypoglycaemic-agents}}

\begin{itemize}
\tightlist
\item
  \textbf{Biguanides}: Metformin

  \begin{itemize}
  \tightlist
  \item
    Insulin \emph{sensitiser}
  \item
    \textbf{Mechanism of action}

    \begin{itemize}
    \tightlist
    \item
      \(\downarrow\) hepatic glucose production (gluconeogenesis and
      glycogenolysis)
    \item
      \(\uparrow\) gut glucose uptake \& utilisation
    \item
      weak inhibitor of mitochondrial respiration \(\rightarrow\;\)
      \(\uparrow\) AMP, \(\downarrow\) ATP \(\rightarrow\;\;\uparrow\)
      glucose uptake utilisation etc.
    \end{itemize}
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Weight neutral
    \item
      Non-hypoglycaemic
    \item
      \emph{Lactic acidosis}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Sulphonylureas}: Glibenclamide, Gliclazide, Glimepiride

  \begin{itemize}
  \tightlist
  \item
    Insulin \emph{secretagogue}
  \item
    \textbf{Mechanism of action:} Block K\(^+\) channel in
    \(\beta\)-cells \(\rightarrow\;\;\uparrow\) insulin secretion
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Wt gain
    \item
      Hypoglycaemia
    \end{itemize}
  \end{itemize}
\item
  \textbf{\(\alpha\)-glucosidase inhibitors:} Acarbose

  \begin{itemize}
  \tightlist
  \item
    \textbf{Mechanism of action}: delay absorption of carbs
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Non-hypoglycaemic
    \item
      Flatulence
    \item
      Bloating
    \item
      Diarrhoea
    \end{itemize}
  \end{itemize}
\item
  \textbf{Incretin-based therapies:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{DPP-4 inhibitors:} Gliptins

    \begin{itemize}
    \tightlist
    \item
      \textbf{MoA}

      \begin{itemize}
      \tightlist
      \item
        DPP-4: breaks down GLP-1 \& GIP \(\rightarrow\) inhibit incretin
        effect
      \end{itemize}
    \end{itemize}
  \item
    \textbf{GLP-1 receptor agonists:} Exenatide, liraglutide
  \end{itemize}
\item
  \textbf{Thiazolidinediones:} Pioglitazone

  \begin{itemize}
  \tightlist
  \item
    \textbf{Mechanism of action}

    \begin{itemize}
    \tightlist
    \item
      PPAR-\(\gamma\) agonist \(\rightarrow\) enhance action of insulin
    \end{itemize}
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Non-hypoglycaemic
    \item
      Wt gain (increase fat cells)
    \end{itemize}
  \end{itemize}
\item
  \textbf{SGLT-2 inhibitors:} empagliflozin, dapagliflozin

  \begin{itemize}
  \tightlist
  \item
    \textbf{MoA:} inhibit reabsorption of glucose in renal tubules
    \(\rightarrow\) 25\% of filtered glucose excreted
  \item
    Resulting glycosuria can lead to genital fungal infections
  \item
    Empagliflozin \(\rightarrow\) 35\% reduced mortality in heart
    failure
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{diabetic-retinopathy-tbf}{%
\section{Diabetic retinopathy (TBF)}\label{diabetic-retinopathy-tbf}}

\pagebreak

\hypertarget{gastrointestinal-diseases}{%
\chapter{Gastrointestinal diseases}\label{gastrointestinal-diseases}}

\hypertarget{weight-loss}{%
\section{Weight loss}\label{weight-loss}}

\hypertarget{causes-5}{%
\subsection{Causes}\label{causes-5}}

\begin{itemize}
\tightlist
\item
  \textbf{Endocrine}

  \begin{itemize}
  \tightlist
  \item
    DM (more in type I)
  \item
    Thyrotoxicosis
  \item
    Addison's
  \end{itemize}
\item
  \textbf{GI}

  \begin{itemize}
  \tightlist
  \item
    Any cause of dysphagia e.g.

    \begin{itemize}
    \tightlist
    \item
      Stroke
    \item
      MS
    \item
      Ca oesophagus
    \item
      Achalasia cardia
    \item
      Plummer-Vinson syndrome (oesophageal webs+IDA)
    \end{itemize}
  \item
    Malabsorption syndrome

    \begin{itemize}
    \tightlist
    \item
      IBD
    \item
      Chronic pancreatitis (due to enzyme insufficiency)
    \item
      Coeliac disease
    \end{itemize}
  \end{itemize}
\item
  \textbf{Malignancies}
\item
  \textbf{Chronic infection}

  \begin{itemize}
  \tightlist
  \item
    TB
  \item
    AIDS
  \end{itemize}
\item
  \textbf{Psychological}

  \begin{itemize}
  \tightlist
  \item
    Depression
  \item
    Anorexia nervosa
  \item
    Bulimia nervosa
  \item
    Alcoholism
  \end{itemize}
\end{itemize}

\hypertarget{haematology}{%
\chapter{Haematology}\label{haematology}}

\hypertarget{chronic-myeloid-leukaemia-cml}{%
\section{Chronic myeloid leukaemia
(CML)}\label{chronic-myeloid-leukaemia-cml}}

Defining characteristic: \textbf{Philadelphia chromosome}

\begin{itemize}
\tightlist
\item
  Shortened \textbf{chr22} by \emph{reciprocal translocation} with
  \textbf{chr9}
\item
  Results in \textbf{BCR-ABL fusion gene}
\item
  BCR-ABL codes for a \textbf{tyrosine kinase} which influences cell
  proliferation and survival
\end{itemize}

\hypertarget{features-12}{%
\subsection{Features}\label{features-12}}

\begin{itemize}
\tightlist
\item
  Wt loss
\item
  Lethargy
\item
  Abdominal discomfort
\item
  Splenomegaly
\item
  Hepatomegaly
\end{itemize}

\hypertarget{phases}{%
\subsection{Phases}\label{phases}}

\begin{itemize}
\tightlist
\item
  Chronic
\item
  Accelerated
\item
  Blastic crisis
\end{itemize}

\hypertarget{investigations-8}{%
\subsection{Investigations}\label{investigations-8}}

\begin{itemize}
\tightlist
\item
  \textbf{CBC:} anaemia, leucocytosis
\item
  \textbf{PBF:}

  \begin{itemize}
  \tightlist
  \item
    Full range of granulocytic precursors, from \emph{myeloblasts} to
    \emph{mature neutrophils}.
  \item
    Predominant: neutrophils and myelocytes.
  \item
    Myeloblasts \textless{} 10\%.
  \end{itemize}
\item
  \textbf{Bone marrow examination: }

  \begin{itemize}
  \tightlist
  \item
    Hypercellular marrow
  \item
    \(\uparrow\) M/E ratio
  \item
    \(\downarrow\) erythrpoiesis
  \item
    \(\uparrow\) leucopoiesis
  \end{itemize}
\item
  \textbf{Chromosome analysis} to detect Ph chromosome
\end{itemize}

\hypertarget{management-10}{%
\subsection{Management}\label{management-10}}

\hypertarget{chronic-phase}{%
\subsubsection{Chronic phase}\label{chronic-phase}}

\begin{itemize}
\tightlist
\item
  \textbf{1st line: Tyrosine kinase inhibitors (TKIs):}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Imatinib}
  \item
    \textbf{Dasatinib}
  \item
    \textbf{Nilotinib}
  \item
    normalise blood count within a month, complete cytogenetic response
    (disappearance of Ph chr) within 6 months in 90\% patients. Resample
    bone marrow at 6mo to confirm. Thereafter monitor 3-monthly by
    RT-PCR for BCR-ABL mRNA transcripts.
  \end{itemize}
\item
  \textbf{Allogeneic HSC transplant:} if TKI fails
\item
  \textbf{Hydroxycarbamide}
\item
  \textbf{Interferon:} in pregnancy
\end{itemize}

\pagebreak

\hypertarget{nutritional-diseases}{%
\chapter{Nutritional diseases}\label{nutritional-diseases}}

\hypertarget{vitamins}{%
\section{Vitamins}\label{vitamins}}

\hypertarget{b_1-thiamin-deficiency}{%
\subsection{\texorpdfstring{B\(_1\) (thiamin)
deficiency}{B\_1 (thiamin) deficiency}}\label{b_1-thiamin-deficiency}}

\hypertarget{functions-of-thiamin}{%
\subsubsection{Functions of thiamin}\label{functions-of-thiamin}}

\begin{itemize}
\tightlist
\item
  Cofactor in different pathways of aerobic metabolism of glucose

  \begin{itemize}
  \tightlist
  \item
    decarboxylation of pyruvate to acetyl-coA (so bridge between
    glycolysis and Krebs)
  \item
    decarboxylation of \(\alpha\)-ketoglutarate to succinate in Krebs
  \end{itemize}
\end{itemize}

\hypertarget{features-13}{%
\subsubsection{Features}\label{features-13}}

\begin{itemize}
\tightlist
\item
  For its pivotal role in aerobic glucose meta, the largest blow is
  dealt to the tissues most dependent on glucose - the \textbf{brain}
  and the \textbf{heart}.
\item
  \textbf{Beri-beri}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Dry:} Neurological beri-beri

    \begin{itemize}
    \tightlist
    \item
      Peripheral neuropathy
    \item
      Wrist/foot drop
    \item
      \textbf{Korsakoff's psychosis}
    \item
      \textbf{Wernicke's encephalopathy}
    \end{itemize}
  \item
    \textbf{Wet:} Cardiac beri-beri (wet as it causes generalised
    oedema)

    \begin{itemize}
    \tightlist
    \item
      Biventricular failure
    \item
      Generalised oedema
    \item
      Pulmonary oedema
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{treatment-6}{%
\subsubsection{Treatment}\label{treatment-6}}

\begin{itemize}
\tightlist
\item
  Wet and Wernicke's should be treated by IV vit-B and C mixture
\item
  Korsakoff's: irreversible, nonresponsive to thiamin
\end{itemize}

\hypertarget{b_12-deficiency}{%
\subsection{\texorpdfstring{B\(_{12}\)
deficiency}{B\_\{12\} deficiency}}\label{b_12-deficiency}}

\hypertarget{functions-of-b_12}{%
\subsubsection{\texorpdfstring{Functions of
B\(_{12}\)}{Functions of B\_\{12\}}}\label{functions-of-b_12}}

\begin{itemize}
\tightlist
\item
  Recycles folate \(\rightarrow\) essential for \textbf{cell division}
  (especially in RBC)
\item
  \textbf{Myelination}
\end{itemize}

\hypertarget{features-14}{%
\subsubsection{Features}\label{features-14}}

\begin{itemize}
\tightlist
\item
  \textbf{Megaloblastic anaemia}
\item
  \textbf{Glossitis}
\item
  \textbf{Neurologic features}

  \begin{itemize}
  \tightlist
  \item
    Peripheral neuropathy
  \item
    Autonomic neuropathy
  \item
    Optic atropy
  \item
    Subacute combined degeneration of spinal cord
  \end{itemize}
\end{itemize}

\hypertarget{treatment-7}{%
\subsubsection{Treatment}\label{treatment-7}}

\begin{itemize}
\tightlist
\item
  Vit-B\(_{12}\) IM
\item
  If combined folate and B\(_{12}\) deficiency, only folate should not
  be given without B\(_{12}\), as B\(_{12}\) gets used up in folate
  recycling, deteriorating the B\(_{12}\) deficiency symptoms. Always
  give both together.
\end{itemize}

\backmatter
\end{document}
